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ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is highly chemo-resistant and has a five year
survival rate of <8%. Risk factors of pancreatic cancer, such as chronic pancreatitis, help to
elicit a pro-tumor immune response, and highly fibrotic environment that promotes
tumorigenesis. To study how chronic pancreatitis promotes cancer initiation, traditional
KRasG12D mice and double mutant Akt1Myr/KrasG12D mice were used to model
microenvironment changes. Akt1Myr/KrasG12D mice were more susceptible to chronic tissue
damage, accelerated tumor development and metastatic disease. These mice exhibited
histological changes consistent with immune cell privilege, where M2 macrophages and
non-cytotoxic eosinophils were co-localized with fibrotic regions. IL-5 expression was up
regulated in pancreatic cells undergoing acinar to ductal metaplasia and then diminished in
advanced lesions. Tumor cells treated with IL-5 exhibit increased migration and activation
through STAT5 signaling. Collectively, the results suggest that eosinophils, which are
responsive to IL-5, are key mediators in the pancreatic environment subjected to chronic
inflammation and injury.
Current therapeutics fall short in increasing patient survival. There remains an
urgent need for innovative treatments and thus we tested difluoromethylornithine (DFMO)
in combination with a novel polyamine transport inhibitor, Trimer44NMe, against
Gemcitabine-resistant PDAC cells. Prior clinical failures when targeting polyamine
biosynthesis with DFMO monotherapy may be due to tumor escape via an undefined
polyamine transport system. In pancreatic tumor cells DFMO alone and with Trimer44NMe
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significantly reduced PDAC cell viability by inducing apoptosis or cell cycle arrest. In vivo
orthotopic PDAC growth with DFMO treatment resulted in decreased c-Myc expression, a
readout of polyamine pathway dysfunction. Moreover, dual inhibition significantly
prolonged survival of tumor-bearing mice, and increased M1 macrophage infiltration and
reduced FoxP3 expression. Collectively, these studies demonstrate that targeting
polyamine pathways in PDAC is a promising immunomodulating therapy that increases
survival.
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CHAPTER ONE: BACKGROUND
History of the Pancreas
Throughout history, the pancreas was generally ignored as an organ. It was assumed that it
lacked a significant function and was unable to be the origin of pathological diseases. The
first description of the pancreas was from the Greek anatomist and surgeon Herophilus.
Born in 33B.C., and one of the founders of the ancient school of Medicine in Alexandria,
Egypt, Herophilus is now considered the Father of Scientific Anatomy1. It was not until 400
years later (1st or 2nd century AD) that Ruphos gave the organ the name “pancreas” or the
Greek word meaning “all flesh, or meat”2. This name was most likely given for its uniform
fleshy consistency and lack of bone or cartilage2. Then a decade later the pancreas was
finally thought to have a purpose. Claudius Galenus (138-201 AD) the “Physician to the
Gladiators” of Rome taught that the pancreas served as a cushion to protect the large
vessels located immediately behind it. His work was undisputable and thus further
pancreatic research was halted for centuries. It was not until 1642 that the enlightening
studies of the pancreas began. German anatomist Johann Georg Wirsüng discovered the
pancreatic duct and definitively established the role of the pancreas as a secretory gland 3.
Wirsüng’s discovery occurred when he was a medical student in Padua, Italy under the
mentorship of Johann Wesling. One year following his discovery he was assassinated. His
mentor Johann Wesling was accused of the murder presumably because of his jealousy for
his student’s success, but was later acquitted of the crime4.
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Over the next 300 years there were advancements in the understanding of the
pancreas’s endocrine and exocrine functions. In 1869, Paul Langerhans a student of
pathology presented his doctoral work encompassing a histological description of the
pancreas, including the discovery of cells that were sequentially named after him, the Islets
of Langerhan5. At this time the significance of the Islets of Langerhan function was still
unknown. Twenty years later, Joseph F. von Mering and Oskar Minkowski proved that total
pancreactomy resulted in diabetes5. Then in 1921 Frederic Grant Banting and Charles
Herbert Best discovered insulin in canine pancreatic extracts5. They determined that
pancreatic extracts would lower blood and urine glucose levels after pancreatic duct
ligation. Fortunately at this time, there was more advanced clinical tests to determine
pancreatic function because prior to the 1800’s, “water testers” tasted patient urine to
determine if it was sweet thereby diagnosing diabetes. Within 6 months of presenting these
findings at the American Association of Physiology research meeting, Banting was urged to
test the extracts in humans5. The first patient was Leonard Thompson who at age 14 was
dying of uncontrolled diabetes5. He was successfully treated with a refined extract and
within 18 months insulin was marketed for clinical use. In 1958 Frederick Sanger, was
awarded the Nobel Prize in Chemistry for the determination of the molecular structure of
insulin6, which lead to new pharmaceutical developments for the treatment of diabetes.
The major surgical advancements for patients with pancreatic cancer have occurred
over the last 100 years. In 1912, Walter Kausch attempted to resect the majority of the
duodenum and significant part of the pancreas7. Then in 1935 Allen O. Whipple published
the seminal report of successful two-stage radical resection of the duodenum and head of
2

the pancreas for ampullary cancer of the head of the pancreas8. This report was on his
findings based from 3 surgical procedures. His first patient died within 30 hours postsurgery due to anastomotic leak, or a leak in the sutured site8. The two other patients died
after 9 and 24 months due to cholangitis and liver metastasis, respectively7. In 1940, the
first one-stage procedure for complete excision of the head of the pancreas and the entire
duodenum by Whipple was recorded7, 9. Due to his groundbreaking achievements Allen O.
Whipple is now known as the “Father of Pancreatic Surgery”. On December 17, 1966, the
first human pancreatic transplant of the modern era was performed at the University of
Minneapolis10. The patient, a 28-year-old female with uncontrolled diabetes and renal
failure received a cadaveric kidney and pancreas, which functioned for almost two
months10.
Pancreatic Cancer: The Deadly Truth
Pancreatic cancer is the third most deadly cancer in the United States. With only an 8.2
percent five-year survival rate11, pancreatic cancer is the most deadly of all major tumor
types. In the year 2017, a projection of 53,670 people will be diagnosed with pancreatic
cancer and approximately 43,000 people will succumb to the disease12. Since 1 in 62 people
are diagnosed with pancreatic cancer13, this is a truly impactful disease and the incidence is
only continuing to rise. By the year 2020, pancreatic cancer is expected to rise to the
second leading cancer mortality, just behind lung cancer14. Since 1975 the number of
deaths per 100,000 people have maintained relatively consistent13, and therefore there has
been relatively no improvement on treatment for these patients. The low prognosis is due
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in part by the lack of effective chemotherapeutic or molecular therapeutics, difficulty of
drug delivery and bioavailability due to the physiology of the tumor. Moreover, there is
difficulty in early detection and screening due to a lack of known biomarkers, and
symptoms do not arise until the cancer has metastasized.
Only 20% of patients with pancreatic cancer have potentially curable disease with
surgical removal of the tumor14. These patients have a localized tumor without any signs
that the cancer has spread to other parts of the body. Chemotherapy with or without
radiation may be given before surgery (neoadjuvant therapy) to shrink the tumor, or after
surgery (adjuvant therapy) to reduce potential reoccurrence. In patients with locally
advanced or metastatic pancreatic cancer the first line of defense is chemotherapy. Until
recently, gemcitabine has been the palliative standard of care for over a decade in patients
diagnosed with pancreatic cancer. Gemcitabine has only an overall 10% response rate and
increases survival by an average of 6.8 months15. In 2010, a combination of four
chemotherapeutic

drugs,

5-fluorouracil,

oxaliplatin,

irinotecan

and

leucovorin

(FOLFIRINOX) became the new standard of care with an increased response rate of 32%
and an improved median overall survival of 11.1 months15. Despite the improvements,
FOLFIRINOX has a much higher toxicity and more severe side effects15, and thus in cases
where patients are weak gemcitabine is still given as a front line therapy.
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Pancreatic Cancer Disease Progression
Acinar-to-Ductal Metaplasia
Acinar cells of the pancreas show the highest plasticity of all adult cell lineages of the
pancreas.16 Pancreatic acinar cells can dedifferentiate into an embryonic progenitor cells
expressing Sox9 and Notch1 and also pancreatic ductal markers including cytokeratin 19
and mucin 1. This process is acinar-to-ductal metaplasia (ADM) and is histologically
characterized by the dilation of an acinus (or cluster of acini) lumen with a duct-like
structure (Fig. 1). It is believed that this ADM is formed in order to allow the pancreas to
regenerate in order to repair damaged tissues. After the damage is repaired and the insult
is removed, cells undergoing ADM are then able to regenerate into normal healthy acinar
cells. However, if there is chronic damage or the presence of genetic mutations in
oncogenes, ADM will be unable to resolve and may continue to develop into precancerous
lesions.

Figure 1: Pancreatic cells undergo acinar-to ductal metaplasia and further transition
to PanINs.

5

Pancreatic Intraepithelial Lesions
Pancreatic Intraepitelial lesions, or PanINs, are a well-characterized morphological process
that is seen throughout pancreatic ductal cancer initiation and progression, and can arise
from ADM. PanINs are staged and classified by the following nomenclature: PanIN-1A,
PanIN-1B, PanIN-2, and PanIN-3. One of the initial genetic changes during pancreatic
cancer is a point mutation in codon 17 of the KRas gene. This point mutation is found in
approximately 95% of pancreatic cancer diagnoses. However KRas hyperactivation is only
responsible for early cancer initiation and without further genetic mutations such as
dysregulation of tumor suppressor genes, tumors rarely progress to PDAC.
Expression of Her-2 also begins during PanIN 1. HER-2 is not expressed in normal
ductal cells but is found at increasing rates through tumor progression, and all specimens
tested with carcinoma in situ had HER-2 expression17. Despite the high prevalence of HER2 expression in PDAC, only approximately 11% of patients have grade +3 overexpression18
and thus HER-2 may be a poor target for therapies. Clinical trails employing antibodies
against HER-2 in combination therapy with chemotherapy does not increase patient
survival compared with single agent chemotherapy.
PanIN 2 lesions are marked by inactivation of tumor suppressor gene p16, and
ablation of p16 is increased through tumor progression. 30% of flat duct lesions, 27%
papillary lesions without atypia, 55% of papillary atypic ducts, and 71% of sample with
carcinoma in situ had loss of expression of the p16 gene product19. Inactivation of tumor
suppressor genes p53, SMAD4 and BRCA2 occur later in PanIN 3 lesions. In pancreatic
carcinomas 50 to 70% have inactivation of p5320, 21, 55% have inactivation of SMAD422, and
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~10% have inactivation of BRCA223, 24. All three appear to be a late event in the genetic
progression as they are fully intact in low-grade PanIN lesions.
Histological Assessment of Pancreatic Intraepithelial Lesions
PanIN lesion classification is based on histological assessment of cell architecture and the
degree of cytological atypia. PanIN lesions are defined as measuring less than 5mm in
diameter25. Due to their size, PanIN lesions are unable to be detected grossly by imaging
techniques, and must be characterized by histological techniques.
PanIN-1A and PanIN-1B are commonly found in normal pancreata, with an
increasing frequency in populations above 40 years of age25. They are epithelial lesions
comprised of tall columnar mucin producing cells with round nuclei located at the basal
membrane. PanIN-1B cells differ in that they show micropapillary or papillary architecture,
as visible by fingerlike projections25.
PanIN-2 and PanIN-3 lesions are rarely found in normal aging populations, however
they may be found in individuals who previously had pancreatitis or other pancreatic
diseases. Both lesions have atypical nuclei. PanIN-2 lesions are usually pseudostratified, or
appear to have multiple cell layers stacked on top of one another due to crowding, however
all cells are attached to the basal membrane25. The cells lack nuclear polarity, meaning that
the nuclei are no longer uniformly located at the plasma membrane. They may also have
nuclear crowding and enlargement. PanIN-3 lesions, or carcinoma in situ, have more severe
architectural and nuclear abnormalities then PanIn-2 lesions. PanIN-3 lesions also present
cribriform architecture, or small clusters of epithelial cells budding off into the lumen of the
duct. Additional histological classifications of PanIN-3 lesions include necrotic lumen,
7

pleomorphism, or variability in size and shape of the nucleus, and abnormal mitotic
epithelial cells25.
Intraductal Papillary Mucinous Neoplasms (IPMNs) are mucin-secreting lesions that
involve the main pancreatic duct and branches. These lesions are greater than 10 mm in
diameter and are generally detected with radiology or clinically. Detection and clinical
intervention are important since these lesions can progress into a malignant tumor.
However, the distinction between low grade PanINs and small IPMNs may be difficult due
to their similar morphology.
Pancreatic Tumor Microenvironment
Pancreatic Stellate Cells Role in Inflammation and Tumor Development
Pancreatic fibrosis and desmoplastic formation are common characteristics of chronic
pancreatitis, and pancreatic cancer. Desmoplasia is produced solely from activated
pancreatic stellate cells (PSCs) which constitute approximately 5% of the total cells of the
pancreas. Fibrotic and collagen-rich stroma reduces the ability of chemotherapeutics to
penetrate into the tumor having little or no effect on tumor burden. On the contrary,
elimination of tumor stroma has been shown to reduce cancer spreading.
PSCs are located in the peri-acinar region of the pancreas stroma, and are usually in
their inactive state. These quiescent cells store vitamin A in lipid droplets. After an
inflammatory response is elicited the inactive PSCs are activated and their phenotype and
physiological function is transformed into a fibroblast-like cell. PSC activation can occur via
cytokines including platelet-derived growth factor (PDGF), transforming growth factor β
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(TGF-β), tumor necrosis factor α (TNF-α), and interleukins (IL)-1, -6, and -1026, 27. The
inflammatory response converts the pancreas stromal environment into a tumor thriving
environment. ILs and TGF-β inhibits the function of effector T cells and Natural Killer (NK)
cells. T regulatory cells are stimulated to help suppress the innate immunity, thereby
producing the ideal tumor growth environment28. The inflammatory response is also
responsible for converting M1 macrophages into M2 pro-tumor macrophages, which
increase cytokine release, angiogenesis, growth, and metastasis29-31. Activated PSCs release
many cytokines including PDGF, FGF, TGF-β, IL-1, -6, -8, CXCL12, MCP-1, and VEGF. Release
of these cytokines further perpetuates PSC activation and enhances the immune response.
Chronic pancreatic inflammation may shift the immune cell population to prime and
remodel the microenvironment, triggering tumor onset.
PSCs also have a direct effect on PDAC cells. Activated PSCs produce extracellular
matrix proteins, increase metastasis, and have a high motility thereby having the ability to
migrate with carcinoma cells during metastasis. PSCs and PDAC cells have a symbiotic
relationship, creating a favorable environment for each other to thrive and proliferate.
PDAC cells incubated with PSC conditioned media, stimulates cancer cell proliferation,
invasion, migration, while also inhibiting cancer cell apoptosis32,

33.

Moreover, PSCs

incubated with PDAC cell-conditioned media activate PSCs, consequently increasing PSC
proliferation, ECM synthesis, and migration32. In-vitro assays show a dose-dependent
relationship between PSCs and PC cells. Increasing numbers of activated human PSCs cocultured with human pancreatic cancer cells increase the tumor cell colony formation,
proliferation, invasion and migration34, 35. Similarly, human PSCs and a human PC cell line
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co-injected orthotopically into the pancreas of nude mice, collaterally migrates to distant
metastatic sites with PDAC cells, and increases angiogenesis, thus priming the environment
for tumorigenesis36. In short, PSCs both indirectly and directly affect cancer cell
progression via hijacking the immune response to provide an environment favoring tumor
growth and via direct PSC-cancer cell interactions.

Figure 2: Pancreatic stellate cell activation and it’s effect on PDAC cells and the
immune cell landscape.
Pancreatic Tumor Infiltrating Leukocytes
Neutrophils
In humans, neutrophils are the most abundant immune cells, and they are the first
responders during inflammation. In pancreatic cancer, neutrophils have been implicated in
early tumor formation, especially when associated with inflammation. Increased levels of
10

neutrophils are found in PDAC and other KRAS-mutant cancer models due to KRAS-driven
up regulation of neutrophil associated cytokines. In humans, increased neutrophil to
lymphocyte ratios (NLR) correlates to poor prognosis. Patients with an NLR < 5 had a
median overall survival of one year, where patients with an NLR> 5 had a medial overall
survival of 4 months37. The neutrophil attractant chemokine CXCL2 is up regulated in
human PDAC and also correlates to poor prognosis38. Deletion of CXCL2 in a murine model
for spontaneous PDAC, results in a significant reduction of infiltrating neutrophils and
abrogation of metastasis38.
Macrophages
Monocytes are located in the bone marrow, and upon maturation, are released into the
bloodstream. Circulating monocytes migrate into tissues where they differentiate into
macrophages. Environmental stimulus, microbial products, and cytokines facilitate
macrophage activation and polarization. Activated macrophages are polarized in to M1, or
classical activated, macrophages primarily by lipopolysaccharide, IFNγ, and GM-CSF. M1
macrophages elicit a pro-inflammatory response by secreting TNFa, IFNγ, IL-12, reactive
nitrogen and oxygen species. M1 macrophages also stimulate a Th1 response, and
important anti-tumor immune response. In contrast, activated macrophages can be
polarized into M2 macrophages by stimulation with IL-4, IL-13 and IL-10. M2 macrophages
have multitudinous roles in tumor formation. In the tumor microenvironment, M2
macrophages secrete various cytokines that promote a Th2 immune response including
increased T regulatory cells, and reduced cytotoxic T cells.
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M2 macrophages also have a role in the formation and remodeling of the
desmoplasic tumor stroma. M2 macrophages secrete cytokines that induce activation of
stellate cells. Moreover, M2 macrophage expression of arginase-1 and L-proline directly
stimulate collagen formation. M2 macrophages also produce factors involved with stroma
turnover, which is implemented during tumor invasion and metastasis. M2 macrophages
produce matrix metalloproteinases (MMPs). MMPs are regulators of tissue homeostasis by
extracellular matrix remodeling. In PDAC, MMPs are important in facilitating tumor
spreading. M2 macrophages also secrete macrophage inflammatory protein-3, which up
regulates MMP9 expression on pancreatic cancer cells. Moreover, M2 macrophages
increase vascularization, and thus a means for metastasis, via stromal remodeling and
secretion of vascular epithelial growth factor (VEGF).
Due to the myriad of pro-tumor roles of M2 macrophages, high numbers of an
increased ratio of M2 macrophages indicates a poor prognosis, and increased liver
metastasis in patients with pancreatic cancer39. Thus targeting macrophages has an
attractive therapeutic strategy in PDAC. Studies have shown that reprograming M2
macrophages into anti-tumor M1 macrophages to increase tumoricidal tumor associated
macrophage (TAM) infiltration, reduce of tumor stroma, and restore of immune
surveillance40.
T-cells
T-cell sub-population infiltration correlates with the progression and prognosis of patients
diagnosed with PDAC. Patients with PDAC have an overall larger CD8+, CD4+ and T
regulator cell population, however patients with a higher T regulator cell ratio directly
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correlated with tumor differentiation, and poorer prognosis. Alternatively, patients with an
elevated CD8+ T-cell population had less differentiated tumors and better prognosis41.
Anti-inflammatory cytokines have a great influence on the alterations of T cell populations
in the microenvironment of a tissue. ILs, and TGF-β inactivates the innate immune cell
function of effector T cells [7]. TGF-β induces T regulatory cell maturation, and mediates T
helper 1 cells to differentiate into pro-tumor T helper 2 cells (Th2). Both T regulator cells
and Th2 cells are stimulated to help suppress the innate immunity, thereby producing the
ideal tumor growth environment28. Dendritic cells are T-cell antigen presenting cells that
are also regulated by the release of TGF-β. In the presence of TGF-β, dendritic cells induce
the maturation of the Foxp3- precursor cells to Foxp3+ CD4+ mature regulatory T cells42.
Mast cells and B-cells
The role of B-cells and pancreatic tumorigenesis has not been extensively studied.
Traditionally, cancer patients elicit a fibroblast secretion of CXCL13 stimulated the
accumulation B-cells in the pancreas of LSL-KrasG12D; p48Cre (KC) mice. Tumorigenesis of
orthotopically implanted tumor cells was decreased in mice lacking B-cells whereas
adoptive transfer of wild-type B-cells restored tumor growth impairment. B-cells have also
been shown to play a role in fibrosis. Blocking IL-10 producing regulatory B-cells reduced
pulmonary fibrosis by modulating the CD4+ T helper 1 cells infiltration in a model of
silicosis43. Moreover, carbon tetrachloride–treated mice lacking B-cells are not susceptible
to liver fibrosis, which is mediated through hepatic stellate cell activation44.
In pancreatic cancer mast cells correlate to a tumor grade and overall patient
survival and increase tumor proliferation and migration, and invasion through and MMP
13

dependent mechanism45. In vitro, mast cell conditioned medium has been shown to induced
pancreatic cancer cell migration, proliferation, and invasion45. Mast cells hyperplasia is
commonly found in many chronic fibrotic diseases including cystic fibrosis, chronic
obstructive pulmonary disease, cholestatic liver disease, and inflammatory bowel disease4649.

Mast cells play a role in initiation of lung fibrosis modulated by lung fibroblast secretion

of the fibrogenic mediators histamine and renin50.
Eosinophils
Eosinophils are a granulocytic innate immune cell whose primary role is maintaining
homeostasis in tissues and providing a defense mechanism in parasitic infections.
Hyperprolliferation and infiltration of eosinophils is found in other pathologies including
various fibrosis associated diseases and cancer.
In many solid tumors, increased eosinophil infiltration into the tumor or eosinophil
degranulation has been correlated with improved prognosis51. Eosinophils can become
cytotoxic against tumor cells by secretion of major basic protein, eosinophil peroxidase,
eosinophil cationic protein, and eosinophil-derived neurotoxin52. Eosinophils co-cultured
with human colorectal cancer cells are tumoricidal by release of eosinophil cationic
protein, eosinophil-derived neurotoxin, TNF-α, and granzyme A53. Moreover, in a model for
fibrocarcoma, eosinophils were shown to be critical for tumor rejection by reducing T
regulatory cells and releasing cytokines responsible for enhancing CD8+ cytotoxic T-cells
recruitment54.
In contrast, there have been reports that correlate increased eosinophil infiltration
to poorer prognosis55, 56. Eosinophils also have pro-tumor effects including their ability to
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orchestrate the tumor immune cell environment and fibrosis development. Eosinophils
stimulate a Th2 immune response, thereby facilitating the polarization of macrophages
from M1 to M2-like TAMs. Eosinophils also secrete cytokine important for T-regulator cell
accumulation57,

58.

Eosinophils store and release a plethora of profibrogenic and

angiogenesis promoting growth factors and cytokines including: tumor growth factor-β1
(TGF-β1), IL-6, IL-8, platelet-derived growth factor, and VEGF59. These released factors
promote fibrosis formation by stimulating fibroblast DNA synthesis, replication, and
increasing collagen production60-62.
The current, but limited studies dedicated to eosinophils in cancer suggest
multifaceted roles in tumor development. Research suggests that eosinophils have the
potential to shape a pro-tumor microenvironment or display direct cytotoxic activities
against tumor cells. This implies that additional mediators in the tumor environment
stimulate the activation state of eosinophils. Studies presented here aim to determine the
role of eosinophils in pancreatic tumor progression as well as to further delineate when
and in what setting eosinophils display antitumorigenic or protumorigenic functions.
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Table 1: Immune Cell Role in Pancreatic Cancer
Immune Cell
Neutrophils
M1
Macrophages
M2
Macrophages
Dendritic Cells
MDSCs
Thelper1 cells
Thelper2 cells
CD8+ cytotoxic
T cells
Regulatory T
Cells
B-cells
Mast Cells
Natural Killer
Cells
Eosinophils

Function
Pro-angiogenic, suppresses antitumor immunity, promotes
metastasis
Pro-inflammatory immune response,
antigen presentation
Immunosuppression, tissue
remodeling
Antigen presentation
Inhibits T-cell activation, suppresses
innate immune system, polarizes
macrophages to M2
Cell mediated immunity,
macrophage activation
Tumor tolerating response
Targets and kills tumor cells
Suppresses activation, proliferation,
and cytokine production of NK cells,
tumor specific CD4+ and CD8+ T cell,
macrophages, and DCs
Tumor-specific autoantibody
response or pro-tumor survival
Increases cell proliferation and
migration
Cytotoxic
Undefined

Adapted by author from published

table63

Secretion of Cytokines
IL-12, TNF α, GM-CSF

Relevance to PC and Prognosis
Present during early initiation then reduces
through tumor development

IL-12, IFNy, TNF-α

Increased in early PanINs and decreased in late
stage PC
Increased in invasive PC and related to tumor size,
reoccurrence, survival
Few in microenvironment, circulating decreased
Increased throughout tumor development,
circulating MDSC correlate to cancer stage,
reduced survival, reduced chemotherapy efficacy
Increased Th1/Th2 ratio correlates to increased
survival
Increased Th2/Th1 ratio correlates to reduced
survival
Reduced throughout tumor development
Increased cells correlated to longer survival
Increased in tumor microenvironment and
peripheral blood
Circulation correlated with reduced survival

IL-4, IL-10, IL-13, MMPs,
VEGF, TNF-α
IL-12,INF-γ
GM-CSF, VEGF, TGF-β
IL-2, IFNy, TNF-α
IL-4, IL-5, IL-6, IL-10, IL13
INF-γ, TGF-α, IL-2
IL-6, IL-10, TGF-β

IL-35

Increased infiltration

IL-1, IL-2, IL-5, IL-6, IL-8,
IL-9, IL-13, TNF-α, VEGF
GM-CSF, IL-3, TNF-α,
INF-γ
IL-5, IL-3, GM-CSF, TNF-α,

Increased infiltration negatively correlates to
patient survival
Positively correlated to survival
Undefined

with the incorporation of information referenced in the introduction.
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Polyamine Based Therapy in Pancreatic Cancer
Native polyamines are involved in a myriad of processes pertaining to cell survival
including: translation, transcription, chromatin remodeling, and autophagy. In many cancer
types, polyamines levels are elevated compared to normal cells and have been shown to be
involved tumorigenesis and metastasis. In particular, polyamine availability to pancreatic
tumor cells is important for tumor cell survival and inhibition of this availability results in
reduced survival in vitro.
Polyamines can be synthesized intracellularly. In short, arginine is converted to Lornithine in the urea cycle. Then decarboxylation of ornithine into putricine is catalyzed by
ornithine decarboxylase (ODC). Putricine is quickly converted from its toxic form to the
biologically useful native polyamine spermidine, which can be further converted into
spermine. These reactions are catalyzed by spermadine synthase (SpmS) and spermine
synthase (SmpS), respectfully. Alternatively, polyamines can be imported or exported via
polyamine transport mechanisms. Two classified mechanisms of transport involve either
direct transport using the plasma membrane transporter SLC12A64 or caveolin-1 (CAV1)
mediated exocytosis.
Due to the extensive pro-survival role of polyamines in cancer, various clinical trials
have incorporated the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO)
as a therapeutic. Promising results have been reported following a stage I clinical trial in
pediatric neuroblastoma. DFMO is now undergoing a stage II clinical trail as a single-agent
preventative therapy for neuroblastoma patients with a high risk for relapse. Preclinical
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studies using DFMO to treat pancreatic cancer in genetic mouse models have significantly
reduced PanIN formation with concentrations as low as 0.1% in the drinking water65.
Unfortunately, clinical trials using DFMO as a single agent treatment for pancreatic cancer
has not proved to be as advantageous as its use in patients with neuroblastoma66.
These discouraging results may be due to the pancreatic tumor cells ability to
import extratumor polyamines. Heparan sulfate proteoglycans (HSPGs) are cell surface
molecules that capture polyamines, increasing endocytotic uptake. Moreover, a cationtransporting ATPase, ATP13A3, has recently been reported to have a suggestive role in
polyamine transport67. Both HSPG and ATP13A3 are up regulated in pancreatic cancer
cells. Furthermore, CAV1, a negative regulator for polyamine import, is down regulated on
pancreatic tumor cells67. In summation, the failure of DFMO treatment in patients with
pancreatic cancer may be due to the tumors ability to circumvent polyamine synthesis
inhibition by importing extracellular polyamines from the microenvironment. Studies
herein, aim to determine if duel inhibition of polyamine synthesis and polyamine import
increase efficacy compared to polyamine synthesis inhibitors alone in pancreatic cancer.
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Figure 3: Polyamine synthesis pathway and polyamine transport inhibitions.
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CHAPTER TWO: CONSTITUATIVELY ACTIVE AKT1 COOPERATES WITH
KRAS(G12D) TO ACCELERATE IN VIVO PANCREATIC TUMOR ONSET AND
PROGRESSION
Preface
This chapter was previously published as an original article in Neoplasia. The article was
published under the Creative Commons Attribution-Noncommercial-No Derivatives
License, and therefore no permissions are required for non-commercial use. This chapter
also previously appears as a chapter in Toya Albury-Warren’s dissertation.
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Abstract
BACKGROUND AND AIMS: Pancreatic adenocarcinoma is a deadly disease characterized by
metastatic progression and resistance to conventional therapeutics. Mutation of KRAS is
the most frequent early event in pancreatic tumor progression. AKT isoforms are
frequently activated in pancreatic cancer, and reports have implicated hyperactivation of
AKT1, as well as AKT2, in pancreatic tumor formation. The objective here is to delineate the
role of AKT in facilitating in vivo pancreatic tumor progression in the context of KRAS
mutation and predisposition to pancreatic cancer. METHODS: Mice with Akt1 and KRas
mutant alleles expressed using the pancreas Pdx promoter were mated to characterize the
incidence and frequency of histologic and genetic alterations known to occur commonly in
human pancreatic ductal adenocarcinoma. RESULTS: Active Akt1 (Akt1Myr, containing a
myristoylation sequence) cooperated with active mutant KRasG12D to accelerate pancreatic
carcinoma onset and progression and increase phosphorylation of downstream effectors in
the Akt pathway. Mucin and smooth muscle actin expression was found in and around
pancreatic intraepithelial neoplasms (PanINs), and accelerated time to metastasis was
found in Akt1Myr/KRasG12D mice. CONCLUSIONS: In contrast to prior reports of pancreatic
KRas mutant mice mated with mice deficient for various tumor suppressor genes, which
resulted in aggressive disease within a few months of age, Akt1Myr/KRasG12D mice enabled
the study of PanINs and spontaneous pancreatic transformation more characteristic of
human pancreatic progression in elderly individuals. The Akt1Myr/KRasG12D model holds
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promise for delineating the tumor biology and biomarkers critical for understanding their
cooperation in cancer oncogenesis and future targeting in therapeutic strategies.
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Introduction
Activating KRAS mutations are present in virtually all human pancreatic adenocarcinomas
and occur with increasing frequency in later stage pancreatic intraepithelial neoplasia
(PanIN) lesions24, 68. To date, the model that most faithfully recapitulates human PanIN
development and its early progression is a mouse model that expresses a Cre-activated
KRas allele knocked into the endogenous KRas locus69 when crossed with mice expressing
a Pdx1-Cre recombinase transgene promoter70. Oncogenic KRasG12D in the progeny of the
Cre matings developed PanINs within a few months, with activation of the Notch pathway
and overexpression of COX-2 and MMP-771. This model thus offered the first recapitulation
of human PanIN lesions, with low incidence of progression to pancreatic adenocarcinoma71.
In comparison, Pdx-Cre;Ptenlox/lox mice with pancreatic knockout of Pten display
rapid progression of pancreatic ductal metaplasia, development of PanINs, and low
frequency of malignant transformation72. Under normal conditions, mouse and human
PTEN functions as a dual-specificity protein phosphatase and a lipid phosphatase. Because
PTEN modulates phosphatidylinositol 3-kinase (PI3K)–AKT signaling, loss of PTEN tumor
suppressor function in pancreatic tumor progression further implicates the importance of
AKT signaling in pancreatic pathogenesis.
Other mouse models of pancreatic cancer have been developed to study
components of the PI3K/PTEN/AKT signaling pathway. A previous study analyzed
constitutively active mutant AKT1 under control of Pdx-Cre, elastase-Cre, and rat insulin
promoter-2–Cre expression73. Interestingly, premalignant lesions and acinar tumors were
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observed when expression was driven by Pdx-Cre. Constitutively active myristoylated
(Myr) AKT1 under rat insulin promoter-2 was also shown to result in malignant
transformation of islet cells to develop islet cell carcinomas74. Most recently, a mouse
model with a constitutively activated catalytic subunit of PI3K was used to study the
importance of PI3K signaling in KRas- driven pancreatic ductal adenocarcinoma (PDAC)
initiation and maintenance75 and the requirement of 3-phosphoinositide dependent
protein kinase 1 (PDK1) signaling for KRas pancreatic cell plasticity and cancer. Of
relevance to human pancreatic cancer, earlier reports showed amplification and protein
overexpression of AKT2 in human pancreatic cell lines76, and both AKT1 and AKT2 were
found in human PDACs and in metastases77. AKT alterations are among the most commonly
activated oncogenic changes in solid tumors and activation of AKT isoforms is frequently
attributed to down-regulation of PTEN tumor suppressor or activation of upstream
signaling components (activating PI3K mutations or activating growth factor receptors). A
prior study, using immunohistochemistry and tissue microarrays, revealed that 34 of 133
(~ 25%) stage II PDACs exhibited loss of PTEN expression78. Haplo-insufficiency and
occasional homozygous loss of PTEN have also been found in human PDACs77. Overall, the
data support a dosage-dependent role for mouse and human PTEN and in the activation of
downstream AKT79.
Herein, we report the first evidence describing the contribution of constitutively
active myristoylated AKT1 in vivo to pancreatic ductal tumor progression using genetically
defined transgenic models to delineate potential cooperation with Pdx-regulated
expression of KRasG12D. Collectively, these studies provide insights regarding the
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pathogenic implication of AKT perturbations in combination with KRas oncogenic
mutations to accelerate pancreatic progression toward the development of invasive PDAC.
In addition, we propose that this dual oncogene model may offer long-term preclinical
utility for testing of novel therapeutic strategies against pancreatic tumor progression and
an opportunity to intervene before extensive desmoplastic fibrosis and irreversible tissue
remodeling, which is a confounding problem in the treatment of late-stage pancreatic
disease.
Materials and Methods
Genetically Engineered Mice
Animal care and use was at Association for Assessment and Accreditation of Laboratory
Animal Care International (AAALAC)-accredited facilities. Protocols were approved by
Institutional Animal Care and Use Committees at each respective institution and were
compliant with NIH guidelines. Pdx-tTA mice in an FVB/n background80 were mated with
TetO-MyrAKT1 mice in a C57Bl/6 to generate Pdx-tTA;TetO-MyrAKT1 mice (Fig. 12). LSLKRasG12D69 in a 129Sv/J background and Pdx-Cre70 mice in a C57Bl/6 were mated to
generate Pdx-Cre;LSL-KRasG12D mice. The progeny were mated to generate litters that
were genotyped using DNA extracted from tail snips (Wizard Genomic DNA Kit; Promega,
Madison, WI) and were monitored for the tumor latency study. In total, 29 Pdx- Cre;LSLKRasG12D (designated KRasG12D mice) and 30 Pdx-tTA;TetO-MyrAKT1 (designated
AKT1Myr/KRasG12D mice) were followed. Animals were housed until times outlined and then
killed in accordance with American Veterinary Medical Association guidelines. Single
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Nucleotide Polymorphism (SNP) analysis performed by Charles River Laboratories
International (Wilmington, MA) on randomly selected mice that were re-derived for the < 1
year analysis revealed that the background of AKT1Myr/KRasG12D mutant mice was ~ 60%
C57Bl/6N.
Genotype Analysis
Reactions were assembled using JumpStart REDTaq ReadyMix (Sigma, St Louis, MO).
Primers for polymerase chain reaction (PCR) detected presence of Pdx-Cre (5′ATCGCTGATTTGTGTAGTCGGT-3′; 5′-CAACAGTTGCGCAGCCTGAATG-3′), mutant or
non-recombined LSL-KRasG12D (5′-GTCGACAAGCTCATGCGGGTG-3′; 5′-AGCTAGCCACCATGGCTTGAGTACGTCTGCA-3 ′ ; 5 ′ -CCTTTACAAGCGCACGCA-GACTGTAGA-3 ′ ),
heterozygous

knock-in

for

tTA

into

the

endogenous

Pdx

gene

(5 ′ -

ACCATGAACAGTGAGGAGCAGTAC-3 ′ ; 5 ′ -GCGGGTTTCAGAGGAATTTGT-3 ′ ; 5 ′ TAGAAGGGGAAAGCTGGCAAG-3′; 5′-TCCAGATCGAAATCGTCTAGCG-3′), or presence of
TetO-MyrAKT1

(5

′

-CTGGACTACTTGCACTCCGAGAAG-3

′

;

5

′

-

CTGTGTAGGGTCCTTCTTGAGCAG-3′).
Histologic Analysis
Specimens were fixed in 10% neutral buffered formalin (Surgipath Leica, Buffalo Grove,IL)
and paraffin embedded. Five-micrometer sections were cut with a rotary microtome
(Leica). Histologic staining used SelecTech hematoxylin and eosin (H&E) reagents
(Surgipath). Staining with Alcian Blue or Trichrome (both from American MasterTech, Lodi,
CA) was performed as per manufacturers' instructions.
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Antigen retrieval for immunohistochemistry was optimized with sodium citrate (pH
6.0) or EDTA (pH 9.0; Leica). Primary antibodies were against phospho-AKT Ser473
(GeneTex, Irvine, CA), phospho-mTor Ser2448 (Cell Signaling Technology, Danvers, MA),
phospho- p70S6K Thr389 (Upstate Cell Signaling, Temecula, CA or LifeSpan BioSciences,
Seattle, WA), and phospho-p70S6K Thr389 (Cell Signaling Technology), mucin-4 (Muc-4;
LifeSpan BioSciences), α-2 smooth muscle actin (α-SMA; Novus, Littleton, CO), cytokeratin
17/19 (Cell Signaling Technology), and Ki67 (Abcam, Cambridge, MA). Detection used
Polymer Refine Detection reagents (Leica). A Bond-Max Immunostainer and Polymer
Refine Detection reagents (Leica) were used.
Cell Culture
Primary cells were collected following the killing of mice, and cells were derived from
phosphate-buffered saline–washed peritoneum and cultured using Dulbecco's modified
Eagle's medium (Cellgro Mediatech, Manassas, VA) supplemented with 15% FBS, 2 mM lglutamine, and 2 mM penicillin-streptomycin. Murine pancreatic cell cultures were
maintained in Dulbecco's modified Eagle's medium/10% FBS supplemented with 2 mM lglutamine and penicillin- streptomycin. Human cell lines were from American Type Culture
Collection (Manassas, VA) and grown as recommended.
Genomic PCR
Genomic DNA was extracted (Wizard Genomic DNA Isolation Kit; Promega), and PCRs were
performed with GoTaq Green Master Mix (Promega). Primers for PCR detected presence of
Tp53 (5′-CTTGACACCTGATCGTTACTC-3′ and 5′-CAGTCCTAACCCCACAGGCGG-3′),
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p16Ink4a (5′-TGGTCACACGACTGGGCGATTG-3′ and 5′- GAATCGGGGTACGACCGAAAG3 ′ ),

p19Arf

(5 ′ -AGCATGGGTCGCAGGTTCTTGG-3 ′

TTGAGGAGGACCGTGAAGCCGA-3 ′ ),
dehydrogenase

or

Gapdh

and

control

and

glyceraldehyde

(5 ′ -AGGCCGGTGCTGAGTATGTC-3 ′

5 ′ -

3-phosphate
and

5 ′ -

TGCCTGCTTCACCACCTTCT-3′).
Western Blots
Whole-cell extracts were harvested from low passage cell cultures with 1 × cell lysis buffer
(Cell Signaling Technology) for protein, 1 mM phenylmethylsulfonyl fluoride (Sigma), and 2
mM Halt protease and phosphatase inhibitor cocktail (Thermo, Waltham, MA). Protein was
quantified using the Bradford method. For Western blot analysis, 60 μg of each protein
extract was combined with Laemmli's sodium dodecyl sulfate sample buffer (final 1 ×) and
denatured in a boiling water bath for 5 minutes. Precision Plus (Bio-Rad Laboratories,
Hercules, CA) protein standard and total protein were separated on 12% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis gels using a Mini-Protean Tetra Cell (Bio-Rad)
unit set for 15 minutes at 20 mA and then 1 hour at 40 mA constant current. Proteins were
transferred to Hybond ECL Nitrocellulose (GE Healthcare Amersham, Pittsburgh, PA) at 25
V at 4°C for 2 hours using an XCell II Blot Module (Invitrogen Life Technologies, Grand
Island, NY). Antibodies for Western blots were against total AKT, phospho-AKT Ser473, and
p53 (all from Cell Signaling Technology), mouse p16Ink4a (Santa Cruz Biotechnology,
Santa Cruz, CA), mouse p19Arf (Abcam), and actin (Millipore, Billerica, MA). Secondary
antibodies were anti-mouse (DyLight, Thermo) and anti-rabbit (IR Dye; LI-COR
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Biosciences, Lincoln, NE), and signals were visualized using an Odyssey Infrared Imaging
System (LI-COR).
Results
Accelerated Frequency of PDACs in Double Mutant Mice Compared to Single Mutant Mice
The pancreatic tumor model uses the Pdx1 pancreas promoter to drive expression of
myristoylated, membrane-targeted, and therefore activated AKT. Specifically, it uses a dual
transgenic system with tetracycline operator (TetO) sequences fused to MyrAKT1 81-83, and
then the progeny were crossed with Pdx-TetA (Pdx-tTA) knock-in mice expressing tTA in
the pancreas80. Resultant Pdx-tTA;TetO-MyrAKT1 transgenic mice were identified by
genotyping (Figure 8).
Transgenic Lox-Stop-Lox (LSL) KRasG12D69 and Pdx-Cre70 mice were expanded, and
these parental mice were mated to obtain compound mice expressing Pdx-Cre–activated
KRasG12D. Resultant Pdx-Cre;LSL-KRasG12D were then mated to Pdx-tTA;TetO-MyrAKT1
mice to generate pancreatic-specific active mutant KRasG12D, active MyrAKT1, compound
mutant AKT1Myr/KRasG12D mice or non-mutant littermates. The progeny were genotyped
and littermates were followed phenotypically to determine if there is cooperation between
mutant active KRasG12D and MyrAKT1 to accelerate malignancy and/ormetastasis and to
establish a potentially clinically relevant pancreatic tumor model useful for future
preclinical studies to test novel targeted therapies.
Figure 4 shows age in weeks when a carcinoma was detected in mice with
compound AKT1Myr/KRasG12D relative to mice with KRasG12D mutant alone. Kaplan-Meier
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curves (GraphPad Prism 5, San Diego, CA) were used to calculate median tumor detection
at 54 weeks in AKT1Myr/KRasG12D mice compared to 74 weeks in KRasG12D mice. At the
median 54-week time point for AKT1Myr/KRasG12D mice, 11 of 22 mice examined had
developed early to full pancreatic carcinoma. In comparison, only one early carcinoma and
one PDAC were found in seven age-matched KRasG12D mice, and tumor progression to PDAC
was significantly delayed in a subset of KRasG12D mice until approximately 15 months of
age. Overall, the number of mice found with early carcinoma to PDAC was 14 of 30
AKT1Myr/KRasG12D and 13 of 29 KRasG12D mice, even though AKT1Myr/KRasG12D mice
declined in health earlier and could not be aged as far as KRasG12D mice. Four metastatic
tumors were found in AKT1Myr/KRasG12D mice at 8 to 12 months of age compared to 0
metastatic tumors in KRasG12D (Table 2). In contrast, littermates that were AKT1Myr mice
had a tendency to develop islet carcinomas (Figure 13), rather than ductal carcinomas, at a
mean latency of 75 weeks in 6 of 24 mice. Because of the predominant islet carcinoma
lineage in the AKT1Myr subset, these mice were not characterized further in the context of
this PDAC study.
Double AKT1Myr/KRasG12D Mice at ≤ 1 Year of Age Exhibit PanINs and PDACs
In a separate experiment, compound mutant AKT1Myr/KRasG12D mice were then studied
within 12 months for the frequency of PanINs and metastatic PDACs. Nearly 77% of
compoundAKT1Myr/KRasG12D mice aged ≤ 1 year exhibited high-grade PanINs and or PDACs
(Table 3). Four of 17 mice developed PDACs. This is consistent with the results from the
Kaplan-Meier study, which showed median histologic detection of malignant tumor
progression at 54 weeks in AKT1Myr/KRasG12D mice (Figure 4).
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AKT Pathway Effector Proteins Are Activated in Early PanINs and Metastatic PDACs
Immunohistochemistry using phosphorylation-specific antibodies depicted abundant AKT
pathway signaling in PanINs and metastatic PDACs (Figure 5). Pathway markers, including
phospho-AKT, phospho-mTor, and phospho-p70S6 kinase were found in the pancreas of
both AKT1Myr/KRasG12D (Figure 5A) and KRasG12D mice (Figure 5B). A possible mechanism
may be increased proliferation, as detected by Ki67 staining, in the PanINs shown in Figure
5A (see Figure 10). Metastatic PDACs in AKT1Myr/KRasG12D mice exhibited ascites and
metastasis to liver or other abdominal sites, with abundant levels of phospho-AKT and
elevated levels of phospho-mTor and phospho-p70S6 kinase at the metastatic sites (Figure
5C).
Markers of Tissue Remodeling in the Pancreas of Mice Undergoing Progression to PDAC
Alcian Blue and Muc-4 staining, markers of mucin expression, were evident in the
pancreatic ducts found in proximity to PDACs. Importantly, Muc-4 is a mucin that has been
implicated as a marker of pancreatic ductal tissue transformation in human PanINs and
PDACs84. In mice, Muc-4 has also been shown to correlate with the progression of
pancreatic cancer from PanIN lesions to PDAC85. Staining for Muc-4 was found in ductal
regions, as well as some acinar regions of AKT1Myr/KRasG12D mice with PDAC (Figure 6).
Similarly, activation of pancreatic stellate cells near centroacinar cells has been implicated
as contributing to desmoplastic or fibrotic areas in PDACs and frequently expresses αSMA86. Recurrent staining for trichrome and α-SMA was found around the acinar regions of
pancreatic tissue with PDAC and PanIN lesions in AKT1Myr/KRasG12D mice (Figure 6A,
representative age 7 months) and KRasG12D mice (Figure 6B, representative age 12
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months). Trichrome stain revealed mild to moderate fibrosis, reminiscent of desmoplasia.
Intensity of trichrome stain was variable, as depicted by green-blue staining (Figure 11) in
a 12-month-old AKT1Myr/KRasG12D mouse. α-SMA staining was frequently detected in
pancreatic acini exhibiting a myoepithelial distribution pattern.
Tumor Cells from Double Mutant Mice Exhibit High AKT Phosphorylation and Loss of Tumor
Suppressors Known to be Important in Human Pancreatic Tumor Progression
Cell cultures were derived from three KRasG12D mice diagnosed with PanINs at age 10 to 11
months and also three AKT1Myr/KRasG12D mice with preneoplastic lesions and/or PDACs at
age 7 to 11 months of age. Western blot analysis revealed high levels of phosphorylated
AKT in low passage cell cultures from AKT1Myr/KRasG12D mice, relative to cells from
KRasG12D mice and two human PDAC cell lines (Figure 7A). For mouse tumors cells, p53
tumor suppressor protein was retained in all cases. Tumor suppressor p16Ink4a protein
expression was frequently downregulated in the cell cultures, with complete loss of
p16Ink4a in one of the AKT1Myr/KRasG12D PDAC cell cultures. P19Arf protein expression
was also difficult to detect, and p19Arf protein was absent in the same PDAC cell culture
with loss of p16Ink4a. Genomic PCR confirmed biallelic loss of the overlapping genes
p16Ink4a and p19Arf, which reside at the Cdk2na locus, in tumor cells from an
AKT1Myr/KRasG12D mouse that developed PDAC (Figure 7B). Such homozygous losses of
CDNK2A are common in human PDACs. Moreover, a tumorigenicity study with this same
PDAC tumor cell culture revealed that it was capable of forming tumors in syngeneic mice
without the mutant alleles at ~ 3 weeks after the orthotopic injection of 1 × 106 cells into
mouse pancreas (Figure 12).
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Figures and Tables
Table 2: Mice with Pancreatic Carcinomas for Kaplan-Meier Analysis

AKT1Myr/KRasG12D mice were collected at < 8 months primarily because of weight loss,
although KRasG12D mice did not exhibit comparable issues.
†Other pathologies in aged KRasG12D mice ≥ 12 months of age included lymphomas,
hepatocellular carcinoma, and lung adenocarcinoma; a lung adenocarcinoma was found in
an aged- matched AKT1Myr/KRasG12D mouse.
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Table 3: Representative Histology of AKT1Myr/KRasG12D Mice up to 1 Year of Age

Fibroadenomatous lesions are also found in 173, 524, 547, 160, 161, 165, 157, 106, and
177-2. Cystic papillary lesion, early cystoadenoma, and intraductal papillary tumor are
found in 524, 192, and 167, respectively. (* metastasis, †carcinomatosis, ʘpapillary)
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Figure 4: Tumor Latency in AKT1Myr/KRasG12D versus KRasG12D mice.
AKT1Myr/KRasG12D mice (broken line) developed pancreatic tumors (PDACs) at a faster rate
than KRasG12D mice (solid line). Curves were significantly different with a P value < .0001
by log rank (Mantel-Cox) or Gehan-Breslow-Wilcoxon tests (GraphPad Prism 5).
*Figure assembled by corresponding author, Dr. Deborah D Altomare, and pathologist, Dr.
Andres Klein-Szanto, at Fox Chase Cancer Center.
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Figure 5: Activation of the AKT/mTor/S6K Pathway in Pancreatic Tumor
Progression.
The panels show representative early ductal pancreatic lesions, similar to human lowgrade PanINs, with strong activation (brown DAB stain) for phospho-AKT, phospho-mTor,
and phospho-p70S6 kinase in PanINs of (A) AKT1Myr/KRasG12D and (B) KRasG12D mice (40 ×
objective). (C) Immunohistochemical staining of primary PDAC and metastatic specimens
from a ~ 43-week-old AKT1Myr/KRasG12D mouse for phospho-AKT, phospho-mTor, and
phospho-p70S6 kinase and cytokeratin 17/19; a set of panels corresponding to PDAC
metastasis to liver (10 × objective and a scale bar corresponding to 200 μm, with boxed-in
close ups from the 40 × objective and a scale bar of 50 μm). In the metastasis panels, L =
liver and T = tumor. Images were acquired using a Leica DM 2000 microscope with a digital
DFC 295 camera.
*Figure assembled by co-first authors, Toya Albury-Warren and Veethika Pandey.
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Figure 6: Pancreatic histologic alterations in AKT1Myr/KRasG12D and KRasG12D mice.
The panels from (A) AKT1Myr/KRasG12D and (B) KRasG12D mice show staining of
representative pancreatic tissues. Sections showed staining for H&E, Alcian Blue staining of
ducts for detection of mucin (dark blue), Muc-4 (brown color) in areas of ducts, trichrome
stain of red acinar cells, and green-blue collagen-rich fibrotic area of the PDAC tumor and
α-SMA marker (brown color) in areas of acinar cells near fibrotic regions. Boxed-in
highlighted areas (10 × objective, scale bar of 200 μm) were magnified for a focal view with
the 40 × objective (scale bar of 50 μm).
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Figure 7: Phospho-AKT and tumor suppressors in mouse and human pancreatic
tumor cells.
(A) (Left) Representative Western blots from each of three KRasG12D (mouse numbers 190,
148, and 117) and three AKT1Myr/KRasG12D (mouse numbers 505, 9C, and 533) tumor cell
cultures analyzed for expression of total AKT, phospho-AKT (Ser473), and tumor
suppressor genes p53, p16Ink4a, and p19Arf. Actin is a loading control. (Right)
Representative human pancreatic tumor cell lines run adjacent to mouse tumor cells
showing relative amount of total AKT, phospho-AKT (Ser473), and actin. (B) Genomic DNA
PCR showing retention or loss of Tp53, p16Ink4a, or p19Arf.
*Figure assembled by co-first author, Veethika Pandey, and author Lina Spinel.
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Figure 8: General construct scheme for generating genetically engineered mice.
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Figure 9: Representative islet carcinomas from aged AKT1Myr mice.
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Figure 10: Ki67 immunohistochemistry for representative PanINs shown in Figure 2,
A and B.
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Figure 11: Representative α-SMA and trichrome staining of pancreas from a 12month-old AKT1Myr/KRasG12D mouse.
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Figure 12: H&E and cytokeratin 17/19 of orthotopically injected AKT1Myr/KRasG12D
PDAC cells (from mouse 533) into a syngeneic mouse that lacked corresponding
mutant alleles.
Primary cell culture derived from a representative AKT1Myr/RasG12D mouse (histology
shown in Fig 2c) was tested for tumorigenicity. One million cells suspended in 50μL PBS
were orthotopically injected into the head of the pancreas of wild-type syngeneic mice
using 28 1⁄2 G syringes. Tumor growth was monitored by ultrasound imaging and
detectable tumor growth was seen 1 week post tumor cell inoculation. The representative
tumor was collected at 3 weeks. (40x Images).
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Discussion
Pancreatic mouse models targeting genes known to be mapped to the histologic and
genetic profile of PDACs have been used to test cooperativity with KRas mutations, as
reviewed elsewhere87. In most cases, the combination of the predisposing KRas mutation
with loss of tumor suppressors, such as p16Ink4a or p53, greatly accelerates malignancy
such that mice frequently die within a few months. In humans, according to 2014 American
Cancer Society projections, the median age of pancreatic cancer detection is 71 years old
and

increases

with

age

(http://www.cancer.org/acs/groups/content/@research/documents/document/acspc038828.pdf). Moreover, in humans, the progression of PanINs to PDAC probably takes
more than a decade to develop88. Thus, the rapid onset of pancreatic disease in compound
KRas/tumor suppressor knockout mice has limited utility for studies relevant to disease in
the elderly and with other non-genetic factors that contribute to disease and treatment.
The overall objective of the current in vivo study was to combine two oncogenic changes
important for cancer progression to accelerate tumorigenesis, while maintaining a time
frame that would align more closely with the physiological progression observed in the
human disease.
Recently, E17K mutations in the AKT1 pleckstrin homology domain have been
found in human pancreatic intraductal papillary mucinous neoplasms (3 of 36), along with
activatingmutations in PI3K or loss of PTEN89. AKT1 E17K mutations were not found in a
previous study of PDACs90, although the number of cases examined (12) was small. Thus,
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the role of the AKT1 E17K mutation is still being defined and may be context dependent. As
proof of principle, we used an AKT1 construct with an N-terminal myristoylation sequence
(MyrAKT1), one of the oldest known constitutively active mutants of AKT191, to directly
test the experimental in vivo role of constitutively active AKT1Myr in the progression from
PanINs to PDAC. In contrast to the E17K mutation, the myristoylation sequence is well
documented as directing AKT to the plasma membrane and facilitating constitutive
activation92, which in turn has been shown to be important for oncogenic transformation93.
In addition to active mutant AKT1, loss of the PTEN tumor suppressor protein or
constitutive activation of receptor-mediated or upstream PI3K signaling is another means
for constitutive activation of AKT isoforms94, 95. Moreover, it has been suggested that loss of
PTEN function and active mutations of KRas may converge to facilitate tumor growth96. In
terms of previous mouse models of pancreatic cancer, it has been suggested that variations
in phenotypes between Pdx-Cre–activated KRasG12D and Pdx- Cre;Ptenlox/lox mice may be
attributed to differences in the relative expression of KRas and Pten within centroacinar
and duct cells. Previously, it was shown that all mice with KRasG12D activation and Pten
homozygous deletion succumb to cancer by 3 weeks of age, and compound mutant mice for
KRasG12D and heterozygous for Ptenlox/+ show accelerated acinar-to-ductal metaplasia,
PanINs, and PDAC within a year79. The high levels of phosphorylated effectors downstream
in the Pten/AKT signaling cascade may be a mechanism to facilitate the ductal pancreatic
tumor progression. In addition, Pdx-Cre;Pten−/− pancreatic knockout mice were shown to
display progressive replacement of the acinar cells, with ductal structures that expressed
mucins.
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In the AKT1Myr/KRasG12D model presented here, tumor onset was accelerated
compared to that observed in the KRasG12D model. The first Kaplan-Meier analysis showed
that AKT1Myr/KRasG12D mice aged 8 to 16 months had the greatest incidence of early or late
carcinomas (12/23 or 52% of the mice in this age group), with 4 metastatic tumors,
compared to only 5 of 14 (35%) of the KRasG12D mice (Figure 8 and Table 1). Overall, only
two KRasG12D mice with metastasis were found at > 16 months of age when more tumors
were found in the KRasG12D group and at an age when only one AKT1Myr/KRasG12D could be
analyzed. The second AKT1Myr/KRasG12D study used re-derived mice when the colony was
transferred to a new institution. It focused on mice aged to 1 year (Table 3) and was
consistent with the Kaplan-Meier analysis in finding PanINs and PDAC, some with
metastasis at less than 1 year of age. We cannot rule out other factors that may contribute
to the decline of health in the AKT1Myr/KRasG12D mice, and these factors may come to light
as we start analyzing the role of the MyrAKT1 construct in facilitating tissue changes by
using the doxycycline-off inducible MyrAKT1 construct in future studies.
Here, we report that PDAC formation in the compound transgenic AKT1Myr/KRasG12D
mice mimicked a subset of histologic alterations found in human pancreatic tumor
progression, KRasG12D and perhaps KRasG12D/Ptenlox/+ deficient mice. Consistently, we
found phosphorylation of AKT and downstream mTor kinase and p70S6 kinase in
AKT1Myr/KRasG12D mice, both in early lesions and in metastatic PDACs (Figure 5). There
also was extensive remodeling of both ductal and acinar components, as evident by
increased mucin, α-SMA, and nearby fibrosis. Similar to other reports implicating Muc-4 as
a marker of pancreatic ductal tissue transformation in human PanINs and PDACs84, Muc-4
46

expression and overall Alcian Blue for both neural and acidic mucins was increased in the
ductal components in PanINs and in focal regions of the PDACs in these mice (Figure 6).
Similarly, moderate to abundant collagen in the stroma was evident in disrupted acinar
regions and around abnormal ducts.
To examine common genetic changes that are known to be important in the
pancreatic tumor progression cascade, tumor cells were derived from the mice
predisposed to pancreatic tumor progression and examined for down-regulation or
occasional biallelic loss of tumor suppressor genes commonly implicated in PDAC. Overall,
the establishment of cell cultures from the KRasG12D mice was challenging, perhaps in part
due to the inefficiency of developing full PDACs until mice had reached an advanced age. A
limited number of primary cultures from AKT1Myr/KRasG12D PDACs were established.
Similar to human pancreatic tumors, genomic PCR and Western blot analysis confirmed
biallelic loss of p16Ink4a and p19Arf tumor suppressor gene expression in representative
PDAC cells from an AKT1Myr/KRasG12D mouse (Figure 7). Moreover, staining for H&E and
immunohistochemistry against cytokeratin 17/19 detected tumors from AKT1Myr/KRasG12D
PDAC cells when they were orthotopically re-injected into the pancreas of a syngeneic
mouse to show tumorigenic potential (Figure 12).
Collectively, compound AKT1Myr/KRasG12D mice exhibited accelerated PDAC
development compared with KRasG12D mice, and the tumors in AKT1Myr/KRasG12D mice
showed histologic and genetic alterations that recapitulate those found in human
pancreatic progression. Thus, this mouse model is likely to be of importance for preclinical
testing of novel therapeutics targeting KRas and/or PI3K/AKT signaling in pancreatic
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cancer. Future analysis of the AKT1Myr/KRasG12D mouse model is expected to elucidate in
vivo contexts in which AKT1 and KRas oncogenes interact in the pancreatic
microenvironment to better facilitate treatment and overcome poor patient prognosis
currently associated with this deadly disease. In particular, we suggest that the model may
have added value for chemoprevention studies to block tumor progression at the PanIN or
early carcinoma stage, perhaps before a stage where there is excessive desmoplastic
damage and fibrosis.
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CHAPTER THREE: IDENTIFICATION OF A NOVEL INTERLUKIN-5
SIGNALING PATHWAY IN CHRONIC PANCREATITS AND CROSSTALK
WITH PANCREATIC TUMOR CELLS
Preface
This paper is currently in submission to the Proceedings of the National Academy of
Sciences.

Gitto, S.B., Oyer, J.L., Litherland, S.A., Cline, K.A., Copik, A.J., Khaled, A.S., Fanaian, N.,
Arnoletti, J.P., Deborah A. Altomare. Identification of a novel interlukin-5 signaling pathway
in chronic pancreatitis and crosstalk with pancreatic tumor cells.
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Abstract
While inflammation is associated with pancreatic cancer, the underlying mechanisms
leading to cancer initiation are still being delineated. To address this, genetically
engineered mice were used to model microenvironment changes induced by chronic
inflammation. Compound Akt1Myr/KRasG12D mice, compared to single KRasG12D or Akt1Myr
mice, were more susceptible to chronic tissue damage, accelerated tumor development and
metastasis. M2 macrophages and newly identified eosinophils co-localized with fibrotic
regions rather than infiltrating into tumors, consistent with immune cell privilege. The
majority of eosinophils found in the pancreas of Akt1Myr/KRasG12D mice with chronic
inflammation lacked the cytotoxic NKG2D marker, suggesting that eosinophils in this
context might support tumor growth. IL-5 expression is important for eosinophils, and
here we found that IL-5 was upregulated in pancreatic cells undergoing acinar to ductal
metaplasia, then diminished in advanced lesions. IL-5Rα, not previously characterized in
pancreatic tumor cells, increased during mouse pancreatic tumor progression and was
expressed in human pancreatic ductal adenocarcinomas (7 of 7 by immunohistochemistry).
Tumor cells treated with IL-5 exhibit increased migration and activation through STAT5
signaling, thereby suggesting an unreported tumor-promoting role for IL-5Rα in pancreatic
cancer. Collectively, chronic inflammation induces pancreatic injury and microenvironment
changes that facilitate pancreatic cancer progression, in part through the attraction of
immune cells such as eosinophils to areas of fibrosis. New findings suggest that IL-5 in the
pancreatic compartment stimulates increased IL-5Rα on ductal tumor cells to increase
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pancreatic tumor motility. IL-5/IL-5Rα crosstalk in mouse and human pancreatic tumors
cells is a novel mechanism to facilitate tumor progression.
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Significance
By 2020, pancreatic cancer is expected to become the second leading cause of cancer
mortality.

Current

treatments

often

do

not

account

for

the

fibrotic

tumor

microenvironment and the complex interplay of immune cells and stromal cells on tumor
initiation. Eosinophils are critical for the progression of fibrotic gastrointestinal diseases
but are understudied in pancreatic cancer. This study addresses whether eosinophils in the
context of chronic pancreatic inflammation have a different phenotype then eosinophils
associated with acute inflammation. Interleukin-5, important for immune cell recruitment
and activation, was expressed by pancreatic cells. Crosstalk of IL-5 with IL-5Rα on
pancreatic tumor cells is a novel pathway that may be targeted to inhibit pancreatic tumor
spreading and improve responsiveness to therapies.
Introduction
With a five-year survival rate of only eight percent, pancreatic ductal adenocarcinoma
(PDAC) is one of the most lethal of all major tumor types. Here we will focus on the
desmoplastic microenvironment and pro-tumor characteristics, which are postulated to
make current chemotherapeutic or immunotherapy treatment challenging97.
Acute insult to the pancreas results in an inflammatory environment, which
promotes anaplasia of the pancreatic cells to a progenitor like state, allowing proliferation
of cells and tissue remodeling to repair the damage. Acinar cells undergo a transition to
become ductal like, and when the acute inflammation is resolved, they are able to transition
back to their acinar phenotype98. Failure to resolve acute inflammation leads to chronic
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inflammation, which will stabilize acinar to ductal metaplasia (ADM)98. Thus, chronic
pancreatitis is an established factor for pancreatic cancer99. Delineating the role of this risk
factor and how it alters the tissue microenvironment to promote tumor onset may lead to
new treatment options.
Pancreatic fibrosis and the desmoplastic phenotype are common characteristics of
chronic pancreatitis and pancreatic cancer. Inflammation causes quiescent pancreatic
stellate cells (PSCs) to become activated and transform into fibroblast-like cells100. PSCs
potentiate changes to the extracellular matrix, such as the secretion of collagen and
periostin (osteoblast-specific factor-2), meanwhile an increasingly fibrotic stroma reduces
the ability of chemotherapeutics to penetrate the tumor101. Activated PSCs also produce
cytokines that recruit immune cells that further perpetuate the production of fibrosis and
promote tumor formation. During chronic inflammation, macrophages are recruited to the
activated stroma and become polarized by local interleukins towards an alternatively
activated tumor associated macrophage (M2) phenotype. M2 macrophages stimulate the
production of collagen through the expression of arginase-1 and L-proline102.
Eosinophils also increase collagen production by fibroblast cells via release of
eosinophil peroxidase (EPO)103. In cancer, the presence of tumor-associated tissue
eosinophilia (TATE) or eosinophil degranulation has been correlated with improved
prognosis51. In some tumors, eosinophils adopt cytotoxic properties against tumor cells via
expression of cytotoxic markers including NKG2D. NKG2D neutralizing antibody was
previously shown to reduce activated eosinophil toxicity against hepatocellular carcinoma
cells104. In contrast, eosinophil infiltration has been linked to poorer prognosis in other
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tumor types including, Hodgkin lymphoma, oral squamous cell carcinoma, and cervical
carcinoma55, 56. Eosinophils stimulate T-cell proliferation and Th2 cell polarization via Th1
apoptosis, as well as shift the microenvironment towards T-regulatory cell accumulation57,
58.

Although eosinophils have been previously reported in pancreatic cancer105, their role

has yet to be defined.
IL-5 is a cytokine that is responsible for the recruitment, proliferation, maturation
and activation of eosinophils106-110. IL-5 enhances eosinophil adhesion and migration on
periostin111. Recent reports indicate that IL-5 has a role in accumulation of pancreatic
fibrosis. Mice lacking IL-5 have reduced eosinophil infiltration and reduced collagen
formation after cerulein injections compared to mice with an intact IL-5 gene112. IL-5 also
stimulates growth and differentiation of B-cells, and can prime mast cells by increasing
their production of pro-tumor and pro-fibrotic cytokines including TNF-α, IL-5, IL-13, MIP1α, and granulocyte- macrophage colony-stimulating factor (GM-CSF)113. In addition, IL-5
promotes collagen synthesis and in the presence of pancreatic stroma may induce
differentiation of M2 macrophages114. To our knowledge, IL-5Rα has only been
characterized in the context of immune cell signaling, and its expression on other tissue
types has not been previously reported.
This

report

aims

to

understand

the

complex

interplay

of

a

fibrotic

microenvironment and the role that pro-tumor immune cell infiltration has on the
progression of pancreatic cancer in the context of chronic pancreatitis. We previously
reported accelerated PDAC formation in genetically engineered mice with myristoylated
Akt1 (Akt1myr) and active mutant KRasG12D (Akt1Myr/KRasG12D)115. The objective for this
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study was to determine if cerulein accentuated tumor development in Akt1Myr/KRasG12D
mice over that of untreated controls or cerulein-treated KRasG12D mice. At parallel times
across the different treatment groups, Akt1Myr/KRasG12D mice exhibited the most severe
pancreatic tissue remodeling and damage response Here, a dominant type II response and
extensive fibrosis likely facilitated infiltration of B-cells and granulocytes, such as mast
cells and eosinophils, in the response to chronic inflammation. Also, findings lead to the
discovery of a new signaling mechanism of crosstalk between IL-5 expression in the
pancreatic microenvironment and IL-5Rα on pancreatic tumor cells, which may be a novel
targetable pathway in pancreatic tumor progression.
Materials and Methods
Tissues and serum were collected from mice after 4 or 8 rounds or cerulein injections as
outlined in Figure 1A and described in the SI Materials and Methods. Tissues were formalin
fixed and processed for histological analysis by a certified pathologist (A.K.). In subsequent
studies, pancreas was collected after 4 rounds of cerulein injections and processed for
immune cell analysis by flow cytometry. Serum collected from mice was used for analysis
of cytokines and amylase activity. For human tissue analysis, tissues were collected at the
time of surgery from consulting patients at Florida Hospital (J.P.A.). Tumor tissue and
nonadjacent normal tissues were collected and prepared for analysis on the day of
resection. Patients were diagnosed (Table S1) and IL-5Rα staining was confirmed by a
certified pathologist (N.F.). All histochemical and biochemical methods are described in
detail in the SI Materials and Methods.
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Clinical Samples
Tissues were collected at the time of surgery from consenting patients at Florida Hospital
under Florida Hospital IRB approved protocol 507397 and used in these experiments only
as HIPAA de-identified tissues.
Breeding and Genotyping
All mice were housed and handled in accordance with protocols approved by the UCF
Institutional Animal Care and Use Committee at the Burnett building at Lake Nona, an
Association for Assessment and Accreditation of Laboratory Animal Care International
(AAALAC) accredited facility. Transgenic mice with activation of KRasG12D (Pdx- Cre;LSLKRasG12D) were mated with transgenic mice with activation of Akt1 (Pdx- tTA;TetOMyrAkt1). Mice were genotyped as previously described115.
Experimental Pancreatitis
At 10-12 weeks of age Wt, Akt1Myr, KRasG12D , and Akt1Myr/KRasG12D mice were divided into
two groups, PBS treated and cerulein treated. Cerulein treated mice were dosed
intraperitoneally with 50μg/kg cerulein once each hour for five hours (one series), every
other week, for up to eight total injection series (American Peptide Company, Sunnyvale,
CA). Control mice from all genotypes received comparable injections of 0.9% sodium
chloride (saline). Serial collections of serum from the submandibular vein, was collected
~16 hours post injections for cytokine and amylase activity analysis. Mice were monitored
daily for diarrhea, signs of distress, and periorbital exudates. Mice exhibiting these signs of
distress were euthanized according to American Veterinary Medical Association guidelines.
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At the termination of the study, mice were sacrificed and tissues were collected at
approximately 16 or 48 hours post the last injection following the fourth or eighth rounds
of injections. Mice were euthanized by cardiac puncture under isoflurane and secondarily
by cervical dislocation. Pancreata, liver, small intestine, and spleen were collected and fixed
in 10% buffered saline for histological analysis or in RPMI to be further processed for flow
cytometry analysis.
Immunohistochemistry
Specimens were fixed in 10% neutral buffered formalin (Surgipath Leica, Buffalo Grove, IL),
paraffin embedded prior to sectioning with a rotary microtome (5um; Leica). Sections
attached to charged microscope slides were dried at 65°C for 30 minutes in a hybridization
oven. Slides were stained for hemotoxilin and eosin (H&E) reagents (Surgipath). Staining
with Trichrome or Combined Eosinophil-Mast Cell (C.E.M.; American MasterTech, Lodi, CA)
was performed as per manufacturer’s instructions.
Immunohistochemisty using Polymer Refine Detection reagents was performed
using the Bond-Max Immunostainer (Leica). Then the tissue was dehydrated and
coverslipped. Antigen retrieval was optimized using sodium citrate, pH 6.0 or EDTA, pH 9.0
(Leica). Primary antibodies used for this study include smooth muscle actin (α-SMA;
Abcam), Periostin (AdipoGen, San Diego, CA), macrophage marker F4/80 (Thermo Fisher
Scientific, Waltham, MA), M2 macrophage marker CD206 (mannose receptor; Bioss,
Woburn, MA), eosinophil marker PRG2 (Bioss), B-cell marker CD19 (Bioss) IL-5 (Santa
Cruz, Dallas, TX), and IL-5Rα (Bioss). Images were taken using a Leica DM 2000 microscope
with 5X, 10X, or 40X objectives
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Histological analysis of chronic pancreatitis and PanIN lesions
124 mice after 8 rounds of cerulein or PBS injections were histologically analyzed for
pancreatitis and staged based on their tumor progression. Tissues were diagnosed with no
pancreatitis, chronic severe pancreatitis (samples with >20% of the acinar area infiltrated
with mononuclear cells and fibrosis) or acute pancreatitis (infiltration of mononuclear cells
without fibrosis). Upon histological assessment, mice were deemed to have incidental
chronic focal, mild pancreatitis as defined by samples with <5% of acinar tissue infiltrated
with mononuclear cells and replaced by fibrosis.
Collagen staining and quantification
Samples were staining using One-Step green and red Trichrome Stain Kit. Three to eight
random fields were analyzed per mouse depending, on the size of the cross section of
pancreas obtained. Area of collagen was determined per field using ImageJ, and the average
area per mouse was calculated (n=7 representative mice).
Flow Cytometry
After the 4th series of cerulein injections mice were euthanized and the pancreas was
collected in cold PBS. For Akt1Myr and Wt pancreas where there was minimal fibrosis, the
pancreas was perfused with RPMI to dissociate immune cells from inside the tissue. For
KRasG12D and Akt1Myr/KRasG12D studies with a higher incidence of fibrosis, the GentleMACs
Dissociator with the Tumor Dissociation Kit (Miltenyi Biotec, Auburn, CA) was used to
dissociate tissue. Cells were then centrifuged at 300 x g, washed with cold PBS and
resuspended with antibodies diluted in staining buffer. For macrophage phenotype
analysis, after the cells were incubated with extracellular marker antibodies the cells were
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fixed and permeabilized using the Fixation/Permeabilization Solution Kit (BD), per
manufacturer’s instructions. Cells were then incubated with antibodies against
intracellular markers, washed and resuspended in staining buffer. A total lymphocyte
analysis in Akt1Myr and Wt was performed by looking at various immune cell surface
markers including CD45 (total lymphocytes), CD3 (T-cells), CD11b (monocytes), Ly6G
(myeloid cells). The macrophage phenotype panel included CD45, F4/80, MHCII, CD206,
and iNOS. The eosinophil panel included CD45, F4/80, CD11c, CD193, SiglecF, and NKG2D
for cytotoxicity. Antibodies were purchased form eBiosciences. Samples were analyzed
using a BD FACSCanto flow cytometer (BD biosciences) or CytoFLEX flow cytometer
(Beckman Coulter, Pasadena, CA), and data was processed with Flowlogic software (Inivai
technologies, Mentone, Australia).
Cytokine Bead Array
Exsanguination by cardiac puncture was performed on mice ~48 hours after the eighth
dose of cerulein. Serum was separated from blood cells by centrifugation at 2,000 x g for 15
minutes in serum separating tubes (BD). Quantitative analysis for IL-5 was performed
using the BD Biosciences Mouse IL-5 Flex Set, Cytometric Bead Array, per Manufacturer’s
instructions. Samples were analyzed using a CytoFLEX flow cytometer. Raw values mean
intensity fluorescent values (MFI) were acquired using Flowlogic software, and data was
processed using Microsoft Excel and GraphPad Prism.
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Amylase Activity Assay
Blood serum was collected from Akt1Myr/KRasG12D, KRasG12D, and Wt mice at 12 weeks of
age, before the study began as a baseline, and ~16 hours after the 6th round of cerulein or
PBS as a control. Amylase activity assay and analysis (Abcam, Cambridge, UK) was
performed per manufacturer’s instructions. Sample absorbance was read at 405 in a
colorimetric plate reader every 5 minutes for 1 hour. Amylase activity was calculated per
milliliter of serum from a standard curve.
Transwell Assay
Transwell pore size and cell number were optimized for both cell lines. 8 x 105 533 and 1 x
106 L3.6pl were placed in the top chamber of a 24-well transwell plate (Corning). Cells
were incubated at 37°C for 4 hours (533) or 6 hours (L3.6pl) with media in the bottom
chamber containing 0ng/mL, 100ng/mL, or 200ng/mL free IL-5 cytokine. The insert was
rinsed with PBS and a Q-tip was used to remove cells from the top chamber that did not
migrate. The insert was fixed for 10 minutes for 4% paraformaldehyde, than washed with
PBS. Inserts were stained with a 1% crystal violet in 2% ethanol for 20 minutes. Inserts
were washed thoroughly with diH2O and air-dried. Using a scalpel the membranes were
cut from the holder and mounted and a coverslip was applied using Permount. The total
number of cells that migrated through the transwell were counted from 5 random fields
and then averaged. After taking into account the viewing area and the total transwell area,
the percent migration was calculated.
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Immunofluorescence
Tumor cells grown overnight on glass chamber slides coated (Thermo Fisher) with poly-Llysine. Cells were washed and fixed with 4% paraformaldehyde for 20 minutes on ice. The
cells were incubated overnight at 4°C with a polyclonal IL-5Rα antibody (Bioss). Cells were
washed and then incubated for one hour at room temperature with an AlexaFloura
secondary antibody, AlexaFlour 488 conjugated Phalloiden and DAPI (Thermo Fisher).
Cells were images using a Zeiss LSM 710 confocal microscope. For Stat5 activation studies,
cells were treated with IL-5 (BioLegend, San Diego, CA) for 5 or 15 minutes prior to fixation
and incubated with phosphorylated Stat5 primary antibody (Cell signaling, Danvers, MA).
Mean fluorescent intensity for phosphorylated Stat5 was calculated by Volocity imaging
software (PerkinElmer, Walthham, MA) for nuclear phospo-Stat5 for each cell in the field
(~7-15 cells for 5-10 fields). Data represents three individual experiments.
Statistical Analysis
When appropriate, results were reported as mean ± SEM. Data were analyzed using oneway ANOVA with Dunnett’s multiple comparisons post-hoc test, or two-way ANOVA with
Tukey’s multiple comparisons post-hoc test, or unpaired Students T-test, when
appropriate. Statistical significance was set at *<0.05, **<0.01, ***< 0.001, ****<0.0001
(GraphPad Prism, La Jolla, CA).
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Results
Chronic inflammation in Akt1Myr/KRasG12D induces severe stromal damage and increases
pancreatic tumor development
Pdx-Cre;LSL-KRasG12D (herein referred to as KRasG12D mice) and Pdx-tTa;TetO-MyrAkt1
mice (herein referred to as Akt1Myr mice) were mated for production of double mutant and
single mutant offspring115. Mice were intra-peritoneally injected every other week with 50
μg/kg cerulein hourly for five hours, for up to 8 rounds of injections (refer to methods and
Fig. 14A). Control mice included wild-type littermates and single mutant Akt1Myr injected
with cerulein (denoted as CCK in figures), which resulted in minimal pancreatic tissue
fibrosis and low numbers of infiltrating immune cells (Fig. 13). Additional controls include
mice injected with PBS as a vehicle control. Wild-type and Akt1Myr PBS-injected mice show
no significant pathological lesions or inflammation (Fig. 13). While KRasG12D and
Akt1Myr/KRasG12D exhibited focal PanIN lesions (Fig. 15).
Histological assessment after eight rounds of cerulein revealed that 80% of the
analyzed Akt1Myr/KRasG12D mice display chronic pancreatitis with widespread fibrosis in
place of acinar cells and infiltration of immune cells (Table 4, Fig. 14B), which was
subsequently defined with additional histochemical assessment. Progression to PDAC was
observed in the Akt1Myr/KRasG12D mice following cerulein injections, and after 24 weeks of
age. Forty percent of Akt1Myr/KRasG12D mice were diagnosed with PDAC, two of which had
terminal disease and were found dead at 23 and 24 weeks of age (Table 4). In advanced
cases, the metastatic sites include the spleen, liver, and small intestine (Fig. 14D). The
previously reported mean tumor latency of Akt1Myr/KRasG12D mice was 54 weeks115, thus
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induction of chronic inflammation resulted in a shift in early tumor latency in the
Akt1Myr/KRasG12D mice.
To quantitate the amount of stromal remodeling in Akt1Myr/KrasG12D mice, we
assessed total area of collagen by trichrome staining. Extensive stromal remodeling in
Akt1Myr/KRasG12D mice resulted in a 40.5% increase in total area of collagen formation
compared to KRasG12D mice (Fig. 14C). Moreover, immunohistochemistry detected
increased expression of smooth muscle actin (SMA), a marker of activated stellate cells, and
periostin deposition (Fig. 14B). After 4 rounds of cerulein injections, Akt1Myr/KRasG12D mice
had early stromal activation detected by SMA expression and precancerous lesions (Fig.
14B). In contrast, KRasG12D mice presented with mainly localized ADM, PanIN precursor
lesions, and acute inflammation as determined by focal neutrophil infiltration (Table 4). By
using both mouse models with this modified cerulein injection strategy, we can analyze a
fibrotic tumor microenvironment in parallel with an acute inflammatory precancerous
model at various stages to better understand the roles of the pancreas microenvironment
on tumor development.
Tumor promoting leukocytes precede PDAC development during chronic inflammation
To analyze the infiltration of innate immune cells during chronic inflammation we utilized
immunohistochemical techniques to delineate the stromal localization and flow cytometry
to analyze immune cell subtypes. Macrophages, one of the most abundant leukocytes and a
well-established regulator of pancreatic cancer, are significantly increased upon induction
of inflammation. Akt1Myr/KRasG12D mice have an increased detection of general macrophage
marker F4/80 following cerulein injections (Fig. 16A). After only 4 cerulein injections,
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Akt1Myr/KRasG12D mice have significantly increased F4/80+ macrophage infiltration
compared with PBS controls mice (n=6 and n=5, respectively, Fig. 16B). Upon analysis of
the total macrophage population in cerulein treated mice, Akt1Myr/KRasG12D mice had a
significant

shift

to

M2

polarized

macrophages

(MHC

class

II+CD206+iNOS-).

Akt1Myr/KRasG12D mice exhibited a 33.3% increase in the ratio of MHC class II+CD206+iNOSmacrophages compared to the PBS injected control mice (Fig 16B). Immunohistological
staining for CD206 showed that there is increased M2 macrophage infiltration in
Akt1Myr/KRasG12D compared to KRasG12D and M2 macrophages primarily localized within
fibrotic regions (Fig. 16A).
Akt1Myr/KRasG12D mice with chronic inflammation also had increased infiltration of
eosinophils as determined by immunohistochemistry for PRG2 (major basic protein, MBP,
Fig. 16A) and combined eosinophil and mast (C.E.M.) staining (Fig. S2C). Eosinophils were
primarily localized in regions of collagen-rich fibrosis of Akt1Myr/KRasG12D mice compared
to KRasG12D mice presenting with acute inflammation. When comparing the staining for the
eosinophil cytotoxic marker NKG2D after 4 rounds of cerulein injections, the majority of
the eosinophil in Akt1Myr/KRasG12D lacks NKG2D expression (67.1%), where only 42.1% of
eosinophils in KRasG12D mice lack expression (Fig 16C). As these results were analyzed
from the same mice that have increased M2 polarization, it can be speculated that M2
polarization

and NKG2D- eosinophils

are activated by

congruently expressed

environmental stimulus.
In addition to eosinophils, there were similar trends for other cell types that are
known to crosstalk with eosinophils. Eosinophils have been reported to promote B cells
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proliferation and support survival in vitro, and peripheral blood eosinophils correlated to
the number of circulating B-cells116. Eosinophils also have numerous known soluble
mediators and ligand/receptor interactions with mast cells117. Immunohistochemistry for
the CD19+ marker of B-cells and C.E.M. staining for mast cells showed increased cell
numbers in fibrotic regions of the pancreas from Akt1Myr/KRasG12D mice compared to
KRasG12D mice (Fig. 16).
IL-5 expression in pancreatic acinar tissue and acinar-ductal metaplastic lesions
IL-5 is secreted by immune cells including mast cells, and is an important activating
cytokine for both eosinophils and B-cells. Thus, IL-5 expression in pancreatic tissues
undergoing chronic inflammation was expected to be found at increasing levels associated
with immune cell infiltration. In the pancreas, IL-5 is found at low mRNA expression levels
(0.2 transcripts per kilobase million or TPM) in the human PDAC cell line Cspan-2 and low
antibody staining has been shown for IL-5 protein expression in the pancreas exocrine
glandular tissue118, 119. Besides expression correlating to immune cells, our results showed
increased expression of IL-5 in ADM cells and early PanIN lesions in KRasG12D mice (Fig.
19A). However, IL5 expression was low at the same time point in Akt1Myr/KRasG12D mice
that had loss of acinar cells and advanced PanIN lesions. These results were surprising
since significant expression levels of IL-5 are mainly reported on immune cells.
Amylase is a marker of acinar cells, and upon inflammation or damage to the acinar
tissue, amylase is released into the blood stream. Here amylase staining showed a similar
trend as IL-5 in which there was increased expression in acinar and ADM cells, than a loss
in pancreatic tissues with chronic pancreatitis and without remaining healthy acinar
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tissues (Fig 19A). Release of circulating amylase was detectable after 6 rounds of cerulein
injections in KRasG12D mice; whereas tissue damage was well established in
Akt1Myr/KRasG12D mice with decreased detection of circulating amylase in the blood (Fig
19B). There was also increased circulating IL-5 in the blood of KRasG12D mice, but
decreased in the blood of Akt1Myr/KRasG12D mice with severely damaged pancreatic tissue
(Fig 19C). However, results did not reach statistical significance, possibly in part due to the
limit of detection for pg/mL IL-5, or transient nature of IL-5 levels in peripheral blood.
IL-5 Rα activation of STAT-5 increases tumor cell migration
IL-5Rα is usually found on both eosinophils and B-cells for activation through IL-5
stimulus, and its expression has yet to be reported on pancreatic tissue. Here we report
that IL-5Rα was weakly expressed during early stages of mouse PDAC initiation, but
expression was increased with tumor progression (Fig. 20A). This is consistent with results
from PDAC cell lines, including two derived from different Akt1Myr/KRasG12D mouse (533
shown and 9C not shown)115, and another from a highly metastatic human tumor (L3.6pl),
which express cytosolic and perinuclear IL-5Rα (Fig 20B). Also, tumorigenic human L3.6pl
and murine Panc02 pancreatic tumor cells retained expression of IL-5Rα when
orthotopically injected into immunocompetent NSG mice or C57Bl6 mice, respectively
(data not shown).
We next examined the effects of tumor cells stimulated with IL-5 ligand. In the
presence of soluble IL-5, murine 533 and human L3.6pl cell migration increased 1.7 and 3.5
fold, respectfully, compared to the untreated control (Fig. 20C). The increase in migration
was not due to an increase in cell proliferation. MTS results after 48 hours of IL-5 ligand
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stimulation in 533 and L3.6pl cells were not significantly different compared to untreated
cells (data not shown). Activation of Stat5, a classical downstream effector of IL-5Rα in
eosinophils, was significantly up-regulated and localized to the nucleus in PDAC cells after
5 minutes of IL-5 stimulation, then reduced to transient levels at 15 minutes (Fig. 20D).
These results are supportive of a prior study highlighting IL-5 as a mediator for migration
and invasion in bladder cancer through MMP-9 activity and Stat signaling120. The finding of
activation of STAT5 in pancreatic tumors is also consistent with previous reports that
suggest it is a molecular target in pancreatic cancer, as it is expressed in 50% of human
PDAC121.
Expression of IL-5 Rα in Human PDAC
IL-5Rα was detected by immunohistochemistry in human PDAC arrays, further supporting
a role in PDAC tumorigenesis (Fig. 21). All seven patients with confirmed diagnosis of PDAC
stained positively with antibody detection for IL-5Rα. Two ampullary carcinomas, two
cholangio carcinomas, a benign case of pancreatitis and a benign bile duct adenoma
resulted in negative detection of IL-5Rα, supporting a specificity for cancerous pancreatic
ductal cells. Patient information and pathology diagnosis is outlined in supplemental table
5.
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Figure 13: Oncogenic Akt1Myr alone does not induce stromal changes and increased
immune cell infiltration with cerulein injections.
(A) Hematoxylin and eosin staining of the pancreas for Akt (top panel) and Wt (bottom
panel) mice injected with 4 rounds of CCK injections (4-month-old) or 8 rounds of CCK
injections (6-month-old) Images were acquired at 10x magnification and the scale bar
denotes 100μm. (B) Flow cytometry results of immune cells collected from perfused
pancreas of Akt and Wt mice after 4 rounds of CCK or PBS as a comparative baseline. Total
lymphocytes were gated first by forward and side scatter then for total lymphocyte marker
CD45. Individual cell populations were then sub-gated according to CD11b+ (macrophages
and monocytes), CD3+ (T-cells), and CD45R (B-cells). A two-way ANOVA and a Tukey’s
multiple comparison analyze statistical significance between means.
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Figure 14: Akt1Myr/KRasG12D mice show profound stromal activation and tissue
remodeling with chronic inflammation.
(A) Schematic of cerulein (CCK) injection strategy shows that all genotypes were are
injected i.p. hourly for 5 hours with PBS or 50μg/kg caerulein bi-weekly for three months.
Mice were euthanized 48 hours (for histology) and 16 hours (for flow cytometry) after the
4th and 8th injections (indicated by the red arrows). (B) Histology of pancreatic tissue for
KRasG12D and Akt1Myr/KRasG12D mice injected with 4 rounds of CCK injections (4-monthold) or 8 rounds of CCK injections (6-month-old). Smooth muscle actin (α-SMA; brown) for
activated PSCs near fibrotic regions. Trichrome staining for acinar tissue (red) & collagenrich matrix (green-blue) in fibrotic areas. Periostin (brown) expression correlating to
regions of activated PSCs and collagen. Images were taken at acquired at 10x magnification
and the scale bar denotes 100μm. (C) Quantification of percent area of trichrome staining
in Akt1Myr/KRasG12D and KRasG12D after 8 rounds of CCK. (n=7 mice, 3 to 8 random fields
were analyzed per mouse). (D) Akt1Myr/KRasG12D mice with chronic inflammation are
prone to developing tumors that metastasize. H&E of Akt1Myr/KRasG12D pancreas tumors
(T) and/or spleen (S) or small intestine (SI) metastasis after cerulein from PDAC diagnosed
mice in table 1.
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Table 4: Akt1Myr/KRasG12D mice with chronic inflammation progresses to more
severe pancreatic cancer and metastasis compared to KRasG12D mice.
Histological Assessment of Pancreas following 8 rounds of CCK injections (6 months of age)
Inflammation
ADM
PanIN 1 PanIN 2 PanIN 3 PDAC Metastasis
Akt/KRas +
CCK
Akt/KRas +
PBS
KRas + CCK
KRas + PBS
Wt + CCK
Wt + PBS

Acute focal: 4 of 10
Chronic: 8 of 10
Acute focal: 10 of 11
Chronic: 2 of 11
Acute focal: 13 of 14
Chronic: 7 of 14
Acute focal: 3 of 13
Chronic: 0 of 13
Acute focal: 0 of 7
Chronic: 0 of 7
Acute focal: 0 of 6
Chronic: 0 of 6

10 of 10

10 of 10

6 of 10

5 of 10

4 of 10

4Ŧ of 10

11 of 11

10 of 11

5 of 11

1 of 11

0 of 11

0 of 11

13 of 14

12 of 14

5 of 14

4 of 14

0 of 14

0 of 14

7 of 13

9 of 13

0 of 13

0 of 13

0 of 13

0 of 13

0 of 7

0 of 7

0 of 7

0 of 7

0 of 7

0 of 7

0 of 6

0 of 6

0 of 6

0 of 6

0 of 6

0 of 6

Acute focal inflammation was scored by defining the presence of neutrophils (IHC staining)
located in and around the ducts. Chronic inflammation was determined by fibrosis
(collagen staining) and increased immune cell infiltration. Pancreatic Intraepithelial
Neoplasia (PanIN), PDAC, and metastasis were scored using defined cellular and structural
changes in the ductal tissue.
Ŧ Mice with PDAC and spleen metastasis were found dead after the 5th and 6th round of
cerulein injections, respectfully. Mouse with the small intestine tumor invasion or liver
metastasis was collected after the 8th round of CCK.
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8

Adenocarcinoma

Figure 15: Immune cell infiltration in pancreatic cancer.
(A) Histological comparison of normal tissue changes due to genetic alterations in
pancreatic tissue from Akt1Myr/KRasG12D and KRasG12D mice with PBS injections at age 4 and
6 months of age. (B) Immunohistochemical staining for CD19 (B cells, brown) and C.E.M.
(mast cells, blue) in Akt1Myr/KRasG12D and KRasG12D mice after 4 and 8 CCK injections. (C)
Eosinophils (C.E.M., red) staining in Akt1Myr/KRasG12D and KRasG12D mice after 8 CCK
injections. (D) Eosinophils (C.E.M., red) in human stage II adenocarcinoma and stage II
adeno-squamous carcinoma.
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Figure 16: Akt1Myr/KRasG12D mice with cerulein-induced inflammation have
increased innate immune cell infiltration.
(A) Immunohistochemistry for Akt1Myr/KRasG12D and KRasG12D mice injected with 4 rounds
of CCK (4-month-old) or 8 rounds of CCK (6-month-old). Tissues with infiltrating immune
cells correlate to prolonged exposure to CCK and are mainly associated to collagen-rich
matrix in fibrotic areas. Immunohistochemistry markers include, total macrophages
(F4/80, brown), M2 macrophages (CD206, MRC1 or C-type mannose receptor 1, brown),
and eosinophils (PRG2, brown). Images were acquired at 10x magnification and the scale
bar denotes 100μm, with 40x magnification inlays. (B) Flow cytometry analysis of
CD45+F4/80+ macrophages and their polarized M1 (CD45+F4/80+iNOS+) or M2
(CD45+F4/80+CD206+MHCII) phenotype from dissociated Akt1Myr/KRasG12D mouse
pancreas after 4 rounds of CCK or PBS. (C) Flow cytometry analysis of percent
CD45+F4/80+CD11c-CD192+SiglecF+ eosinophils without cytotoxic receptor NKG29 from
dissociated Akt1Myr/KRasG12D and KRasG12D pancreas after 4 rounds of CCK injections.
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Figure 17: Gating strategy for identification of M1 and M2 macrophage populations.
Lymphocyte populations were gated by analyzing the width and height of forward and side
scatter, and were positive for CD45. Macrophages were gated on mature murine
macrophage marker F4/80. M2 macrophages were defined as positive for membrane
bound MHC class II and CD206, and negative for intracellular iNOS. M1 macrophages were
defined as positive for iNOS but negative for MHC class II and CD206.
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Figure 18: Gating strategy for identification of cytotoxic and non-cytotoxic eosinophil
populations.
Lymphocyte populations were gated by analyzing the width and height of forward and side
scatter. Eosinophils were gated on the innate lymphocytes marker CD11b and cytokine
receptor CD193, which is highly expressed on eosinophils. CD11c+ cells were excluded and
eosinophil marker SiglecF+ cells were gated for cytotoxicity. After gating, cytotoxic
eosinophils are NKG2D+ and not cytotoxic eosinophils are NKG2D-.
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Figure 19: IL-5 expression in pancreas exocrine cells undergoing acinar-ductal
metaplasia.
(A) Immunohistochemistry for IL-5 and amylase in Akt1Myr/KRasG12D and KRasG12D mice
injected with 4 or 8 rounds of CCK. Images were acquired at 10x magnification and the
scale bar denotes 100 μm. (B) Amylase activity measured in quantity (mU) per milliliter,
from blood serum collected from Akt1Myr/KRasG12D, KRasG12D, and Wt mice 16 hours after 6
rounds of CCK and vehicle control. (C) Concentration of IL-5 in blood serum 48 hours after
the 8th round of CCK injections.

77

A.

PanIN1

PanIN3

C.

B.

PDAC

533 Migration in response to
IL-5 Stimulation

Percent
Cell Migration

25

*

20
15
10
5
0

Untreated

200ng/ul

Percent
Cell Migration

L3.6pl Migration in response to
IL-5 Stimulation
8

4
2
0

Untreated

Untreated

200ng/ul

5 min
p-STAT5
25

**

**

20

ROI

P-STAT5

D.

*

6

15
10

Merge

5
0

0

5
15
Time (minutes)

Figure 20: IL-5 Rα signaling activates Stat5 and promotes migration in PDAC cells.
(A) Immunohistochemistry for IL-5Rα in increasing stages of pancreatic cancer in
genetically modified mouse model. (B) Immunofluorescent staining and confocal imaging
for IL-5Rα (green), phalloiden (red), and nucleus (DAPI, blue) in human L3.6pl cells (top)
and murine derived cells from Akt1Myr/KRasG12D mice (bottom). (C) Transwell assay
analysis of total percent migration of 533 and L3.6pl cells in the presence of soluble IL-5 (0
or 200ng/mL) (n=3). (D) Confocal microscopy and MFI quantification for phospho-Stat5
(green) in L3.6pl cells treated with IL-5 for 5 or 15 minutes. Red phalloidin and blue DAPI
shown in merged images (63x).
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Figure 21: IL-5Rα is expressed in human pancreatic cancer.
Immunohistochemistry for IL-5 Rα in human pancreatic cancer in patient samples.
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Table 5: Patient information and pathology for tissue samples evaluated for IL-5Rα.
IL-5
Staining
+

Tumor
Group
PDAC HI
NEO

Gender

Pathology
Grade
T1N1M0
stage IIB

LN #

M

Age at
Surgery
59.9

+

PDAC HI
NEO

F

77.9

+

PDAC HI

F

65.2

+

M

65.3

+

PDAC HI
NEO
PDAC NEO

F

77

+

PDAC HI

F

79

+

PDAC HI
NEO
Cholangio
carcinoma

M

70

M

65.3

-

Cholangio
carcinoma

M

-

Ampullary

-

-

Pathology Diagnosis

NEO_Adjuvant

1/16

Current
PFS
15

PDAC; poor diff; GS; noninvasive

T3N1M0
stage IIB

3/12

12

T1N0M0
stage I
T3N0M0
stage IIA
T3N1M0
stage IIB,
T3N1M0
stage IIB

0/10

24

0/6

5

1/12

UNK

PDAC; G3 poor diff; invasive;
chronicpancreatits; esophageal
inflammation; fungal infection
PDAC well diff invasive large IPMN with high
grade dysplasia
PDAC, extrapancreas extension; moderately
diff
Poor diff PDAC

NEO Fulfurinox,
radiation; responded
(G3->G1)
NEO Abraxane
gemcitabine

3/34

8

T3N1M0
stage IIB
T3N1M1
stage IV

5/16

13

5/18

6

60

T3N1M0;
stage IIB

3/20

1

M

73.5

0/3

9

Benign

M

84

T4N1M0
stage III
Benign

0/16

2

Benign

M

77

Bile duct
adenoma

0/9

n/a

PDAC; poor diff; G3; invasive low grade
IPMN; squamous component; perineural
invasion; distal pancreatic cancer
PDAC; well diff with mucinous features;
invading duodenal wall and soft tissues
Poor diff bile duct adenocarcinoma; met to
pancreas, duodenum, liver, met; invasion
small bowl, ampullary, peritoneum; G3
Poor diff bile duct adenocarcinoma;
invading duodenal wall, pancreas and
peripancreatic adipose
Poor diff; invasive; in peri-ampullary; thru
small bowel; bile duct
Benign; lymphoplasmacytic
sclerosingpancreatitis
Bile duct adenoma, no invasive carcinoma

none
NEO Abraxane
gemcitabine
NEO
none

none
NEO Abraxane
gemcitabine
none

none
none
none

Abbreviations: diff: differentiated; IPMN: intraductal papillary mucinous neoplasm, LN: lymph node, met: metastasis,
NEO: neoadjuvant therapy; PDAC: pancreatic ductal adenocarcinoma; PFS: progression free survival; sm: small; unk:
unknown.
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Figure 22: Proposed mechanism for IL-5 secretion and tumor migration.
(1) Upon inflammation (2) pancreatic stellate cells become activated and secrete collagen
and periostin. (3) Acinar cells begin to undergo acinar-to-ductal metaplasia and secrete IL5, (4) which recruits eosinophils into the microenvironment. Eosinophils are retained in
the microenvironment by periostin secreted pancreatic stellate cells. Prolonged
inflammation further converts ADM cells into PanINs. PanIN lesions and pancreatic tumor
cells express IL-5 receptor. (5) When IL-5 receptor is bound by IL-5, (6) STAT 5 signaling
pathway is activated which leads to (7) tumor cell migration by a possible MMP dependent
mechanism.
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Discussion
Herein, we present a detailed description of changes to the pancreatic microenvironment
and leukocyte infiltration identified using genetic mouse models. Primarily, we found that
Akt1Myr/KRasG12D mice exhibited accentuated severe chronic pancreatitis when injected
with cerulein, which led to accelerated pancreatic tumor progression. As a component of
the chronic inflammation, we found increased M2 response was detected in mice with
fibrotic disease, which corresponded to an increased Th2 associated infiltration of
granulocytes and B-cells. Our observations are consistent with previous studies of
eosinophil function in fibrotic disease tissues and their influence in regulating a Th2immune response57, 58.
Eosinophils have been proposed as pivotal to several aspects of tissue remodeling
by activating fibroblasts to increase collagen production and fibrosis59. In this study
eosinophils were found in increasing numbers in regions of desmoplasia in both
experimentally induced chronic pancreatitis and human stage II PDAC. Previous reports
have shown that eosinophils may provide a tumor-killing role in some solid tumors,
however there is a gap in knowledge regarding the role of eosinophils in pancreatic
cancer51. Infiltrating eosinophils lacked a cytotoxic receptor, NKG2D, in mice exhibiting
fibrosis. In contrast, eosinophils express NKG2D in tissues with focal and diffuse
pancreatitis. These findings provide evidence to support the assertion that desmoplasia
may provide a unique niche conducive to polarizing eosinophils towards a tumor
promoting phenotype. This study also corroborates previous reports of perilobular and
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interacinar periostin upregulation in chronic pancreatitis122. Periostin has been reported to
increase eosinophil migration and activation, and may be a mechanism that facilitates an
increased number of eosinophils in chronic pancreatitis123, 124.
A second mechanism for eosinophil recruitment in PDAC may be in response to local
secretion of endogenous IL-5 from damaged acinar tissue during pancreatitis. Results here
suggest that there is a low level of IL-5 expression in normal pancreatic cells, but IL-5
expression increases during acute inflammation in cells that have undergone ADM. IL-5
expression is downregulated after cells have undergone transformation to PanIN precursor
lesions.
We found that, PanIN lesions and PDAC cells express increased levels of IL-5Rα, and
PDAC cells have increased migration and Stat5 activation in the presence of soluble IL-5.
STAT5 activation increases chemotherapeutic resistance125 while its inhibition in PDAC is
associated with reduced tumor growth and metastasis121. Therefore, IL-5 Rα and its
downstream activation of oncogenic STAT5 signaling may provide a strategy for novel
molecular therapeutics.
We postulate that acinar damage in response to inflammation can cause the release
of IL-5 into the microenvironment, which in turn helps to recruit eosinophils and B-cells
into the microenvironment. Concurrently, increased periostin deposition results in the
accumulation and retention of immune cells such as eosinophils in the stromal regions.
This prolonged Th2-associated immune response helps to perpetuate the fibrotic buildup
as well as tumor development (Fig. S.5) Overall, cytokine/ receptor switching in pre-
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neoplastic lesions might be a novel mechanism for how cells adapt their expression of
cytokine receptors to utilize the microenvironment for malignant progression.
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CHAPTER FOUR: DIFLUOROMETHYLORNITHINE COMBINED WITH A
POLYAMINE TRANSPORT INHIBITOR IS EFFECTIVE AGAINST
GEMCITABINE RESISTANT PANCREATIC CACNER
Preface
This paper is currently under editorial review at the American Chemical Society Journal for
Molecular Pharmaceutics.

Gitto, S.B, Pandey, V., Oyer, J.L., , Copik, A.J., Hogan, F.C., Phanstiel, O., Altomare, D.A.
Difluoromethylornithine combined with a polyamine transport inhibitor is effective against
gemcitabine resistant pancreatic cancer. ACS Molecular Pharmaceutics.
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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is highly chemo-resistant and has an extremely
poor patient prognosis, with a survival rate at five years of <8%. There remains an urgent
need for innovative treatments. Targeting polyamine biosynthesis through inhibition of
ornithine decarboxylase with difluoromethylornithine (DFMO) has had mixed clinical
success due to tumor escape via an undefined transport system, which imports exogenous
polyamines and sustains intracellular polyamine pools. Here we tested DFMO in
combination with a polyamine transport inhibitor (PTI), Trimer44NMe, against
Gemcitabine-resistant PDAC cells. DFMO alone and with Trimer44NMe significantly
reduced PDAC cell viability by inducing apoptosis or diminishing proliferation. DFMO alone
and with Trimer44NMe also inhibited in vivo orthotopic PDAC growth, and resulted in
decreased c-Myc expression, a readout of polyamine pathway dysfunction. Moreover, dual
inhibition significantly prolonged survival of tumor-bearing mice. Collectively, these
studies demonstrate improved targeting of polyamine pathways against PDAC, leading to
increased survival in pancreatic cancer.
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Introduction
Cancer cells have altered metabolism to facilitate proliferation and growth126. In addition,
pancreatic cancer cells are notoriously resistant to chemotherapeutic treatment with
Gemcitabine (Figure 23). Although patients usually have a good initial response, tumor
cells frequently have intrinsic or acquired resistance to Gemcitabine. This can lead to
escape of pancreatic tumors from the chemotherapeutic treatment. Thus, new efforts are
needed to circumvent these characteristics, and instead exploit metabolic differences
between normal and pancreatic tumor cells. One such mechanism may be reflective of
different polyamine dependencies and alterations in polyamine metabolism68, 127.
The native polyamines (putrescine, spermidine and spermine; see Figure 23) are
low molecular weight aliphatic amines that are essential for cell growth and have critical
roles in translation, transcription and chromatin remodeling68. Intracellular polyamine
levels are balanced by polyamine biosynthesis via ornithine decarboxylase (ODC) and
import

via

the

polyamine

transport

system

(PTS).

The

ODC

inhibitor,

difluoromethylornithine (DFMO, Figure 23), has been used as a chemopreventative agent
in a pancreatic genetic model128 and for other human tumors129. However, there is a high
probability that tumors escape DFMO therapy by upregulating import to replenish
intracellular polyamine pools.
An alternative approach to blocking polyamine synthesis is the creation of
polyamine transport inhibitors (PTIs), such as AMXT-1501130 and more recently
Trimer44NMe131

(Figure

23).

Trimer44NMe,
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or

N(1),N(1'),N(1″)-(benzene-1,3,5-

triyltris(methylene))tris(N(4)-(4-(methylamino)butyl)-butane-1,4-diamine,

contained

three N-methylhomospermidine motifs131. Trimer44NMe was previously evaluated for the
ability to inhibit the import of spermidine in DFMO-treated Chinese hamster ovary (CHO)
and L3.6pl human pancreatic cancer cells131. Several design features affected potency,
sensitivity to amine oxidases, and cytotoxicity. Characteristics included: (a) the number of
polyamine chains appended to the core ring system, (b) the polyamine sequence, (c) the
attachment linkage of the polyamine to the aryl core, and (d) the presence of a terminal Nmethyl group.
The PTIs do not support cell growth and out-compete native polyamines for cellular
entry. Therefore, these PTIs provide a way to pharmacologically address the tumor escape
pathway by inhibiting polyamine import. Mammalian cells can import polyamines by
carrier-mediated, energy- and Na+-dependent mechanisms132,

133.

Transporters with

different affinities for putrescine, spermidine and spermine have been biochemically
characterized134, 135, and differences in Na+-dependence for import have been reported136.
However, the precise mechanisms of polyamine transport in mammalian cells remains
elusive and are likely more complex than a single transporter. Indeed, the development of
PTIs can provide important tools and potential therapies for other diseases, which rely on
polyamine import, such as parasitic diseases137.
Approximately 90% of pancreatic cancers have activating mutations of K-Ras, and
the downstream c-Myc oncogene also has been shown to be overexpressed in both primary
and metastatic pancreatic tumors.138 KRas increases polyamine uptake in human cells139,
and the transcription factor Myc has been linked to polyamine signaling pathways through
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ODC140. Myc expression has also been shown to modulate polyamine uptake and cell
growth141. DFMO treatment to inhibit polyamine metabolism was shown to lead to
increased cyclin-dependent kinase inhibitor p27 (Kip1) protein and caused p27(Kip1)/Rbcoupled G(1) cell cycle arrest in neuroblastoma cells with MYCN gene amplification through
p27(Kip1) phosphorylation142. DFMO has also been shown to inhibit in vivo pancreatic
tumor progression in a KRas-driven mouse model by modulating ODC signaling and cell
proliferation128.
Since the combination therapy of DFMO and a polyamine transport inhibitor
(DFMO+PTI) inhibits polyamine biosynthesis and also addresses the tumor escape
pathway associated with polyamine import, we evaluated DFMO+PTI therapy in the
treatment of pancreatic cancers. Here we demonstrated that DFMO+PTI therapy reduced
tumor growth both in vitro and in vivo through apoptosis and decreased proliferation. We
also confirmed that DFMO treatment reduced oncogenic c-Myc expression in pancreatic
tumors, and that polyamine pathway-targeted treatments may be more effective in
C57Bl/6 mice compared to nude mice. Survival in the presence of tumor significantly
improved with the combination of DFMO and PTI. Collectively, these results suggest that
DFMO+PTI provides a novel way to target cancers with high polyamine requirements and
could represent a new treatment strategy to increase the overall survival of pancreatic
cancer patients.
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Materials and Methods
Materials
Gemcitabine was purchased from Selleckchem (Houston, TX). DFMO was provided by P.
Woster (Medical University of South Carolina, Charleston, SC). The Trimer44NMe PTI131
was provided by O. Phanstiel (UCF, Orlando, FL).
Cell Culture
L3.6pl pancreatic tumor cells was a gift from I. Fidler (MD Anderson Cancer Center,
Houston TX). Pan02 was obtained from the Division of Cancer Treatment and Diagnosis
(DCTD) Tumor Repository (Frederick, MD). L3.6pl and Pan02 cells were grown in
RPMI1640 or DMEM media, respectively, with 5% fetal bovine serum and 1%
Penicillin/Streptomycin and incubated at 37°C in a 5% CO2 atmosphere.
Cell Viability
Cell growth was determined by measuring formazan formation from the 3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfenyl)-2H tetrazolium, inner
salt, using a CellTiter 96 Aqueous One Solution Cell Proliferation Assay (MTS assay;
Promega, Madison, WI). 1 x 103 L3.6pl cells or 2 x 103 Pan02 cells were plated per well and
allowed to adhere overnight at 37°C in a 5% CO2 atmosphere. Respective compounds were
added such that the final concentrations were 75 µM Trimer44NMe PTI, or 9 mM DFMO
with L3.6pl and 0.5 mM DFMO with Pan02. The cells were treated with single agents or in
combination and incubated for 48 and 72 hours, after which a MTS assay was performed.
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The plate was incubated for 2 hours, followed by measuring relative absorbance at 490 nm
with a plate reader.
Flow Cytometry
2 x 105 L3.6pl cells and 4 x 105 Pan02 cells were grown in a 10 cm dish overnight at 37°C
(5% CO2). Respective compounds were added such that the final concentrations were 75
µM Trimer44NMe PTI, or 9 mM DFMO with L3.6pl and 0.5 mM DFMO with Pan02. Cells
were treated with single agents or with a combination thereof for 72 hours. Free-floating
and adherent cells were collected for apoptosis and necrosis analysis using a FITC Annexin
V Apoptosis Detection Kit I (BD Biosciences, San Jose CA). Cells were incubated with
Annexin V in staining buffer for 15 minutes on ice. PBS was added to dilute the cells and 1
µL propidium iodide per 250 µL volume was added. The cells were immediately analyzed
with the BD FACSCanto flow cytometer (BD Biosciences).
Cell Trace Violet Protocol
Pan02 cells (1 x 106 cells) were stained with CellTrace Violet (Thermo Fisher, Waltham,
MA) per the manufacturer’s recommendations. After staining, cells were plated at 5 x 103
cells per mL in complete culture medium. Cells were incubated at 37°C for 1-2 hours to
allow for cell attachment. Cells were then treated with 0.5 mM DFMO, 75 µM Trimer44NMe
PTI or a combination of 0.5 mM DFMO and 75 µM PTI. After 72 hours, cells were
trypsinized, pelleted and then resuspended in PBS and analyzed using the CytoFLEX flow
cytometer (Beckman Coulter, Pasadena, CA). Results were analyzed using FlowLogic
software (Inivai Technologies, Mentone, Australia).
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In Vivo Testing
Experiments were in accordance with the Guide for the Care and Use of Laboratory
Animals and approved by the University of Central Florida Institute of Animal Care and Use
Committee. Human pancreatic L3.6pl tumor cells or mouse pancreatic Pan02 cells (~0.5-1
x 106 in PBS) were injected into the pancreas of nude (nu/nu) mice or C57Bl/6 mice,
respectively (Charles River Laboratories, Fredrick, MD). Seven days after tumor cell
inoculation for L3.6pl and up to 2-3 weeks after tumor inoculation for Pan02, animals were
randomized into groups. Treatment was as indicated with DFMO in the drinking water for
2 weeks and/or PTI administered i.p. for 5 days per week for 2 weeks.
Histological Analysis
Specimens were fixed in 10% neutral buffered formalin (Surgipath Leica, Buffalo Grove, IL)
and paraffin embedded. 5-mm sections were cut with a rotary microtome (Leica).
Histological staining used SelecTech hematoxylin and eosin reagents (Surgipath). Antigen
retrieval for immunohistochemistry was optimized with sodium citrate, pH 6.0 or EDTA,
pH 9.0 (Leica). Primary antibodies were against Ki67 (Novocastra, Newcastle upon Tyne,
UK), cleaved caspase-3 (Cell Signaling Technology, Danvers, MA), ODC (Origene, Rockville,
MD), and c-Myc (Abcam, Cambridge, MA). A Bond-Max Immunostainer and Polymer Refine
Detection reagents (Leica), which included 3,3'-Diaminobenzidine (DAB) chromogen, were
used.
Statistical Analysis
Results are reported as mean ±SEM. Data were analyzed using one-way ANOVA with
Tukey’s multiple comparisons post-hoc test, when appropriate (GraphPad Prism, La Jolla,
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CA). Survival curve data were analyzed using Log-rank Mantel-Cox. Statistical significance
was set at *p<0.05, **p<0.01, ***p< 0.001, and ****p<0.0001.
Results
L3.6pl and Pan02 are Gemcitabine-resistant pancreatic tumor cell lines.
Gemcitabine is a deoxycytidine analogue that is widely used as an anti-cancer
chemotherapeutic agent (Figure 23). We tested L3.6pl human and Pan02 mouse PDAC
tumor cell lines for Gemcitabine responsiveness in comparison to human Panc-1 PDAC cells
that are reported to be Gemcitabine resistant, and control mouse pancreatic cells from a
KRas (KC) mouse with earlier pancreatic lesions (190 KRas)143 that we predicted would
retain sensitivity to Gemcitabine. As shown in Figure 24, L3.6pl and Pan02 cell viability
were not significantly different at any Gemcitabine concentration tested. Both were
statistically more resistant than Panc-1 cells at 100 and 1000 nM Gemcitabine. All three
resistant cell lines had significantly increased viability over that of 190 KRas cells at 100
nM of greater concentrations of Gemcitabine (Two-way ANOVA with Tukey’s multiple
comparison test, GraphPad Prism). Overall, the cytotoxicity curves of Gemcitabine in both
L3.6pl and Pan02 pancreatic tumor cells were consistent with Gemcitabine resistance that
is typical of other PDAC tumor cells lines, such as Panc-1.
Polyamine targeted therapies were effective in pancreatic tumor cell lines.
Previous in vitro studies provided strong rationale for further evaluation of the PTI in
pancreatic cancer cells and in vivo models131,

144.

DFMO dosing was based on previous

determination of cell specific IC50 values for cells plated at a density of 5 x 102 cells per
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mL144. Pan02 cells were more sensitive to single agent DFMO than L3.6pl cells, so the
concentration of DFMO used for the Pan02 tumor cells was lower.
Cell viability was assessed (using MTS reagent) in both L3.6pl and murine Pan02
cells treated with single and combination inhibitors for 48 and 72 hours (Figure 25A).
L3.6pl cells following 48 and 72 hours of treatment showed significantly decreased cell
viability compared to untreated controls, and all treatments showed significant differences
from one another (p<0.0001), with the exception of untreated vs. Trimer44NMe PTI. The
most significant effect on cell viability was observed in the combination treatment of
DFMO+Trimer44NMe compared to untreated cells. For Pan02 at 48 hours, all treatments
were significantly different from control untreated cells and from one another (p<0.001 to
p<0.0001). The combination treatment also had the most significant effect on cell viability.
At the 72 hour time point for Pan02 cells, although cell viabilities were significantly
different compared to untreated control cells and different from one another (p<0.0001),
untreated vs PTI, and DFMO vs. DFMO+PTI, were no longer significantly different.
Collectively these experiments showed that the Trimer44NMe PTI had low toxicity when
dosed alone at 75 μM with an increased cell density of 1 x 103 L3.6pl cells per well for
L3.6pl and 2 x 103 Pan02 cells per well. Furthermore, cells dosed with PTI significantly
reduced cell viability when used in combination with DFMO.
We further tested the differences in viability to determine if they were due to the
induction of apoptosis at the 72 hour time point in the L3.6pl and Pan02 tumor cell lines.
Figure 25B shows that there was a significant increase in the number of L3.6pl cells
undergoing apoptosis, as detected by Annexin V staining, in both the DFMO and DFMO+PTI
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treatments (p<0.05 by ANOVA with Tukey’s multiple comparison test, GraphPad Prism)
relative to untreated cells by flow cytometry. As indicated by the MTS results in Figure 25A,
both the DFMO and DFMO+PTI combination therapies also reduced overall metabolic
activity in Pan02 cells. Rather than inducing apoptosis, treatment of Pan02 cells with DFMO
and DFMO+PTI resulted in inhibition of cell division, as analyzed by Cell Trace Violet
fluorescent flow cytometry (Figure 25C). Overall, both cell lines were highly responsive to
DFMO and the DFMO+PTI combination. Certain cells such as L3.6pl are likely to be more
sensitive to apoptosis in response to DFMO and DFMO+PTI combination, whereas other
cells such as Pan02 are likely to be more susceptible to disrupted proliferation. This may, in
part, be explained by their relative sensitivities to DFMO144.
DFMO but not PTI alone inhibited L3.6pl tumor cells in the pancreas of nude mice.
Given that L3.6pl cells showed sensitivity to apoptosis in cell culture, we wanted to
determine if this was the case in vivo. The dose of DFMO was determined in a nude (nu/nu)
mouse model following orthotopic injection of human L3.6pl tumor cells into the pancreas
and one week seeding time in order to determine which of the treatment dosages were
sufficient to significantly reduce tumor formation relative to placebo-treated mice. DFMO
was dosed in the drinking water at 0, 1, 2 and 3% (weight/volume) for 2 weeks. The drug
was well tolerated in all groups.
Anti-tumor effect was detected by immunohistochemical staining for cleaved
caspase-3 as a marker of apoptosis and Ki67 as a marker of cell proliferation (Figure 26A).
Mice treated with 1% or 3% DFMO clearly showed tumor staining for apoptosis, as shown
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by increased levels of cytoplasmic cleaved caspase-3 (Figure 26A). Tumors also had
diminished cell proliferation, as detected by decreased nuclear Ki67 staining.
A reduction in average tumor weight was observed for mice treated with DFMO
compared to untreated mice. The greatest statistical difference in tumor weight was
observed in the group of mice receiving 3% DFMO in the drinking water (Figure 26B), even
though an observation was made that mice drank less of the 3% DFMO solution.
We also determined the maximum tolerated dosage (MTD) of the Trimer44NMe PTI
in mice orthotopically injected into the pancreas with L3.6pl tumor cells. Mice were treated
with Trimer44NMe at 1 mg/kg and 5 mg/kg injected intraperitoneally (i.p.) once daily on
weekdays for 2 weeks (i.e., 10 days of treatment total) (Figure 26C). Neither of the doses
showed any significant decrease in tumor weights, but mice treated with 5 mg/kg of
Trimer44NMe exhibited diminished physical appearance and activity, suggesting reduced
tolerability of the PTI at this dose. Subsequent experiments used a dose of ~2 mg/kg
Trimer44NMe once daily. Although PTI as a single agent treatment had limited success in
this pancreatic tumor model, we anticipated that a combination treatment with DFMO
would be more effective in reducing tumor escape.
DFMO and the DFMO+Trimer44NMe had anti-tumor effectiveness against pancreatic tumors.
Next, we tested the effectiveness of a combination treatment of DFMO+PTI at inhibiting
tumor growth compared to either agent alone. Immune-compromised nude mice were
used to test the human L3.6pl pancreatic tumor cell lines, whereas immunocompetent
C57Bl/6 mice were used to test the Pan02 mouse pancreatic cancer cell line (Figure 27).
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Overall, results showed that all DFMO-treated mice in both pancreatic tumor models
demonstrated a statistically significant reduction in tumor weight. Notably, the
combination of DFMO and the Trimer44NMe PTI was at least as effective as DFMO alone,
whereas treatment with the Trimer44NMe PTI at 1.8 mg/kg alone did not yield a
significant reduction of tumor weight compared to that of untreated mice. Median tumor
weights for orthotopic L3.6pl amd Pan02 tumors after treatment with DFMO, PTI or
combination are shown in Figure 27.
There were several caveats in using tumor weights to measure efficacy in these
models. For example, tumor progression is different in the two models and results at the
selected time point may not have been sensitive enough to detect additional treatment
group differences in tumor weight. Indeed, tumor weights in the L3.6pl orthotopic model
were difficult to determine because tumors often metastasized beyond the pancreas. As a
result, weights often included normal pancreas and spleen as part of the measurement.
Tumor weights in the DFMO and DFMO+PTI treated Pan02 model typically were smaller
than the L3.6pl tumors at the time point collected, and thus were often difficult to
distinguish from normal pancreas with accuracy. While smaller tumors were suggestive of
efficacy in vivo, we looked at other methods to assess therapeutic outcomes.
Immunohistochemistry showed reduced tumor growth in mice treated with DFMO and
DFMO+PTI.
Immunohistochemical markers collectively showed reduced growth of tumor cells in vivo.
There was visibly less staining for ODC, Ki67 and c-Myc in tumors treated with 1% DFMO
of the combination treatment compared to untreated of PTI treated mice in Figure 28. No
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difference in staining was found for 1% DFMO compared to 1% DFMO+PTI treatments.
Cleaved caspase-3 was not examined because we had already shown that 1% DFMO alone
could induce apoptosis in this mouse model (Figure 26).
Staining of Pan02 tumors in C57Bl/6 mice showed histology consistent with
reduced tumor size with the combination drug treatments (Figure 29). Focal tumor
nodules were found along with normal pancreatic tissue in the combination treatment as
assessed by H&E (Figure 29, 5x objective of 1% DFMO+PTI). Tumor cells that stained
positive for Ki67 were reduced in the DFMO, DFMO+PTI, and also PTI treated mice relative
to the untreated mice. Cleaved caspase 3 staining did not appear to be significant for the
treatments of the Pan02 tumor (not shown), consistent with the in vitro cell culture
experiments. Additionally, tumor cells that stained positive for c-Myc were decreased in all
treatments relative to the untreated tumors (Figure 29).
Trimer44NMe PTI with DFMO increased overall survival.
Previous results have shown that therapies targeting polyamine metabolism do not act
exclusively as anti-proliferative agents, but also may prevent tumor escape from immune
surveillance145. Thus, we tested the ability of the combination of DFMO and Trimer44NMe
PTI to increase survival of immunocompetent C57Bl/6 mice orthotopically injected with
Pan02 tumor cells. All experiments up to this point were done with an experimental cutoff
to look at tumor size relative to that in untreated mice. In order to determine if the
combination treatment resulted in improving the efficacy of single agents and extending
the longevity of the mice, the DFMO dose was decreased to 0.25% (weight/volume) in the
drinking water, similar to other recent studies146. Also, Pan02 tumors were allowed to seed
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for an additional week because growth was slower and tumors were smaller in the Pan02
model compared to the L3.6pl model.
As shown in Figure 30, the mice treated with single agent DFMO or Trimer44NMe
PTI did not have significantly increased survival compared to the untreated group or the
combination treatment. In comparison, DFMO+PTI treated mice survival was significantly
increased (Log-rank Mantel-Cox test, p<0.0009). The mean survival time of mice in the
combination treatment group (34 days post treatment) was nearly doubled compared to
the untreated group (18.5 days post treatment). These experiments indicated that the
Trimer44NMe PTI shows improved efficacy, when combined with DFMO, in prolonging
survival in this PDAC model.
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Figure 23: Structure of Gemcitabine, native polyamines (putrescine, spermidine and
spermine), DFMO, and the polyamine transport inhibitors (PTIs) Trimer44NMe, and
AMXT-1501.
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Figure 24: Gemcitabine resistance of pancreatic tumor cell lines.
MTS assays tested human L3.6pl, mouse Pan02, as well as control human Panc-1 and 190
cells derived from a mutant active KRas (KC) mouse with pre-neoplastic lesions. Cells were
treated with various doses of Gemcitabine for 72 hours (n=3).
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Figure 25: Human L3.6pl and mouse Pan02 pancreatic tumors cells demonstrate
sensitivity to DFMO and PTI.
(A) 1 x 103 L3.6pl and 2 x 103 Pan02 cells were treated with single and combination
inhibitors. ‘PTI’ in the above graphs denotes the Trimer44NMe PTI (75 µM). After the
specified incubation time, cell viability was determined by the MTS assay. Results are
expressed as percent survival in treated cells relative to untreated cells. Each time point
was performed 3 times with six replicate wells. Lines aboe the graphs indicate statistical
significance of ****p<0.0001, or ***p<0.001 in the case of Pan02 at 48 hr untreated
compared to PTI. (B) Apoptosis/ necrosis assayed by flow cytometry in L3.6pl cells plated
at 2 x 105 cells per 10 cm dish, after 72 hours of treatment with 0.5 mM DFMO, 75 µM PTI
or combination treatment. Data represent mean ± SD (n=3). *p<0.05. (C) Cell proliferation
determined by flow cytometry in Pan02 cells plated at 4 x 105 cells per 10 cm dish at 72
hours. Cells were treated with 75 µM PTI and/or 9 mM DFMO. The data is representative of
four experimental replicates.
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Figure 26: In vivo single agent DFMO was effective against L3.6pl in nude mice,
whereas single agent Trimer44NMe was not as effective.
(A) Immunohistochemistry for cell proliferation (Ki67, brown) and apoptosis (caspase-3,
brown) in mice with L3.6pl tumors treated with 1% or 3% DFMO treatment. 10x objective
views are shown. Scale bars correspond to 200 µm. (B) Tumor weights of orthotopically
injected L3.6pl cells in nude mice following the absence or presence of DFMO for 2 weeks
in the drinking water. Data represent mean ± SD (n=5) **p<0.01. (C) Tumor weights from
mice during maximum tolerated dose determination of Trimer44NMe PTI. Less tolerated
dose of 5 mg/kg and well-tolerated dose of 1 mg/kg was administered once a day for 5
days over a course of 2 weeks of treatment. Data represent mean ± SD (n=5).
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Figure 27: DFMO and the combination with Trimer44NMe PTI decreases tumor size.
Drug doses were 1% DFMO in the drinking water for 2 weeks and 1.8 mg/kg Trimer44NMe
PTI injected i.p. once daily for 5 days per week over 2 weeks. Data represent mean ± SD
(n=5)*p<0.05, **p<0.01. (Left) Median tumor weights for orthotopic L3.6pl tumors after
treatment with DFMO, PTI or combination. (Right) Median tumor weights for orthotopic
Pan02 tumors.
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Figure 28: Cell growth was decreased in treated L3.6pl derived tumors in nude mice.
Immunohistochemistry for ODC, Ki67 proliferation marker and c-Myc (brown) are shown.
Scale bars on the 10x objective images correspond to 100 µm.
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Figure 29: Cell proliferation and oncogenic c-Myc was reduced in treated Pan02
derived tumors in C57Bl/6 mice.
Hematoxylin and eosin (H&E) stain, Ki67 proliferation marker and c-Myc immunostains
(brown) are shown. Scale bars on H&E 5x objective images are 500 µm. Scale bars on
immunohistochemistry 40x objective images are 50 µm.
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Figure 30: C57Bl/6 mice with Pan02 pancreatic tumors exhibit longer survival when
treated with DFMO in combination with PTI Trimer44NMe compared to all other
groups.
Pan02 tumor cells (0.5 x 106) were injected into the pancreas of C57Bl/6 mice and allowed
to grow for 2 weeks. Kaplan Meier curves for survival (n~8 for each treatment). As
depicted in the chart below the graph, survival was significantly increased for mice treated
with combination of 0.25% DFMO + 1.8 mg/kg PTI compared to untreated mice (Log-rank
Mantel-Cox test, p=0.0009), but single agent treatments did not statistically increase
survival compared to untreated mice (p>0.05).
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Discussion
DFMO is currently being tested in several Phase I and II clinical trials, alone and in
combination with various other therapeutics, for treatment of neuroblastoma and other
neoplasms. However, cancer cells treated with DFMO may overcome polyamine depletion
by the uptake of polyamines from extracellular sources.
Hence, the experiments here tested the Trimer44NMe PTI, which previously was
shown to exhibit low toxicity against normal cells, decreased sensitivity to exogenous
addition of amine oxidases and high potency in inhibiting the uptake of spermidine (1 μM)
in DFMO-treated L3.6pl human pancreatic cancer cells131. Trimer 44NMe PTI has minimal
toxicity when tested alone, especially when used on cell lines that were previously shown
to have high sensitivity to DFMO131. Tumor size or weight alone was not a good indicator of
response to the combination DFMO and Trimer44NMe. However, immunohistochemical
markers and survival studies did show the benefit of using a combination treatment with
DFMO and Trimer 44NMe.
ODC is of interest because previously, ODC activity was reported to be elevated by
3.6-fold in adenocarcinomas and 3.9-fold in neuroendocrine tumors compared to control
pancreas147. Inhibition of ODC activity caused decreased cell growth and increased
apoptosis in pancreatic tumor-derived cell lines147. In a chemoprevention study of DFMOtreated KRas genetically engineered mice, decreased ODC staining and mRNA was
observed in pancreatic lesions and tumors in mice fed DFMO-supplemented diets
compared to pancreatic tissues of control diet fed mice65.
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In addition, ODC has been shown to be transactivated by c-Myc148, and c-Myc was
identified as a key effector of cell proliferation downstream of RAF→MEK→ERK signaling.
RNA interference of c-Myc expression had anti-proliferative effects in some pancreatic
tumor cell lines similar to that of MEK inhibition, thus confirming the importance of c-Myc
in supporting pancreatic cancer cell maintenance149.
In a prior study, c-Myc protein expression was assayed in 162 pancreatic cancer
patient specimens150. Kaplan-Meier survival analysis revealed that high levels of c-Myc
cytoplasmic expression was significantly correlated with decreased survival of pancreatic
cancer patients (p=0.012). Additionally, multivariate Cox model analysis showed that the
significant independent prognostic factors for overall survival were tumor differentiation,
lymph node status and c-Myc cytoplasmic expression (p<0.001, p=0.023, p=0.001,
respectively)150.
Collectively, the data shows that in vivo implanted pancreatic tumor cell lines are
susceptible to inhibition of polyamine synthesis by DFMO and show significant reduction in
tumor growth in orthotopic models. Based on c-Myc and Ki67 staining, in vivo Pan02
tumors in C57Bl/6 mice may be more sensitive to blockade of polyamine transport by
Trimer44NMe, when used alone, compared to L3.6pl tumors in nude mice. Combination
therapy (DFMO+PTI) resulted in inhibition of tumor progression similar to DFMO alone
based on tumor weight, although histological assessment of the Pan02 tumors showed that
the combination therapy maybe more effective in this tumor model.
To ultimately demonstrate the importance of a treatment strategy based on both
DFMO and Trimer44NMe, and to demonstrate an improved strategy of blocking tumor
109

progression, we showed that a combination therapy of DFMO+Trimer44NMe PTI had
improved effectiveness in doubling the survival of tumor-bearing mice orthotopically
injected with PDAC cells. These results were consistent those of another polyamineblocking therapy that combined DFMO with AMXT-1501 (an inhibitor of the polyamine
transport system shown in Chart 1). The strategy was shown to block tumor growth in
immunocompetent mice, but not in nude mice lacking T cells145. Moreover, mice treated
with a polyamine-blocking therapy one week before surgical resection of engrafted
mammary tumors were resistant to subsequent tumor re-challenge145. A recent study
showed that the combination of DFMO and Trimer 44NMe stimulates an immune effect that
is T-cell dependent against tumors146. It remains to be determined if pancreatic tumors
show similar findings with the combination treatment.
Conclusions: In summary, a combination therapy of DFMO+Trimer44NMe PTI was
shown to nearly double the survival of tumor-bearing mice orthotopically injected with
Pan02 cells. These experiments demonstrated that targeting both polyamine biosynthesis
and import has therapeutic value in the treatment of Gemcitabine-resistant PDAC as
evidenced by decreased expression of proliferation markers like Ki67 and reduced c-Myc
expression compared to untreated mice.
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CHAPTER FIVE: CONCLUSION
By 2020, pancreatic cancer is expected to become the second leading cause of cancer
mortality. Current treatments options are chemotherapeutics such as gemcitabine and
FLOINOX. These therapeutics have only increased survival up to 1 year, and they do not
account for the fibrotic tumor microenvironment and the complex interplay of immune
cells and stromal cells on tumor initiation.
Approximately 95% of all human pancreatic cancer tumors has mutant active KRas,
therefore the most widely studied murine model of pancreatic cancer is the KRasG12D
model. This model recapitulates the initiation process of PDAC. However, these mice tend
to only progress to PanIN lesions and further development to PDAC is rare. Other GEM
models for PDAC have been created to overcome this pitfall by crossing KRasG12D mice with
other mice with a knocked out allele for a tumor suppressor gene such as Tp53 (KPC mice)
or p16 and p19. These mice tend to develop tumor formation very rapidly and die within a
few months151. Since pancreatic cancer usually occurs in the aging population, KPC mice
may not be the most relevant mouse model in which to study a tumor cascade that usually
takes approximately 10 years to develop in humans. During the premalignant stages of
pancreatic tumor development there are significant genetic changes, an influx of various
immune cell populations, and stromal alterations. This progression cascade may not be
properly expressed in models that speed up the tumor progression. Chapter 2 discusses in
detail, a murine model that overcomes the shortcomings of other current genetic murine
models of PDAC.
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In comparison to KRasG12D mice, Akt1Myr/KRasG12D mice have accelerated tumor
formation. Akt1Myr/KRasG12D mice develop histologically detectable tumors at an average of
54 weeks of age where as KRasG12D mice develop tumors at 74 weeks of age. Unlike
KRasG12D mice, Akt1Myr/KRasG12D mice mostly develop and die from PDAC and have an
increased incidence of metastasis. Akt1Myr/KRasG12D mice also undergo relevant early onset
progression, as determined by mucin 4 producing PanIN lesions, and microenvironment
changes, including increased activated stellate cell activation. Akt1Myr/KRasG12D mice
provide a novel tool in which to study the spontaneous pancreatic tumor progression in its
entirety. Thus, it is more characteristic of human pancreatic progression in elderly
individuals.
Desmoplasia is a pathological hallmark of pancreatic cancer and is marked by a
drastic increase in proliferative activated pancreatic stellate cells and increased
extracellular matrix deposition. Fibrotic and collagen-rich stroma reduces the ability of
chemotherapeutics to penetrate into the tumor having little or no effect on tumor burden.
This desmoplastic reaction is one of the primary reasons for which current treatment
strategies do not work in pancreatic cancer. Likewise, patients with chronic inflammation
of the pancreas often display a similar desmoplastic phenotype making the clinical
distinction between chronic pancreatitis and pancreatic cancer difficult.
Pancreatitis is the number one most hospitalized gastrointestinal condition in the
United States, and is a condition resulting from activation of pancreatic digestive enzymes
before they are secreted to the small intestine. These active digestive enzymes irritate
pancreatic cells causing inflammation and fibrosis. Repetitive acute incidences can lead to
112

chronic pancreatitis. Damaged and malfunctioning pancreata may emanate further
complications, including pancreatic cancer. In fact, patients suffering from chronic
pancreatitis have a 10 to 20-fold increased risk for developing pancreatic cancer in their
lifetime. The mechanism like between pancreatitis and pancreatic cancer is still unknown.
To study the link between chronic pancreatitis and pancreatic cancer, the
Akt1Myr/KRasG12D model was employed in the study presented in chapter 3.
Akt1Myr/KRasG12D and KRasG12D were interperitoneally injected with the cholecystokinin
analog cerulein (CCK) to experimentally induce chronic pancreatitis. After side-by-side
comparison, Akt1Myr/KRasG12D with chronic CCK injections have severe increased
desmoplasia, marked by extensive collagen deposition, increased tumor progression to late
stage PanIN lesions, and increased metastasis.
Akt1Myr/KRasG12D mice had infiltration of innate and adaptive immune cells that are
known to create a pro-tumor niche. Macrophages have been shown to be important in
tumor regression or progression depending on their phenotype. M1 macrophages have
been shown to be helpful in fighting the tumor. They recruit cytotoxic lymphocytes, reduce
the desmoplastic reaction and increase patient survival. M2 tumor associated macrophages
release cytokines that simulate the recruitment of additional harmful immune cells. These
immune cells set up an immune surveillance or a blockade of tumorcidal immune cells from
penetrating

the

tumor,

thus

inhibiting

immunoreactivity

against

the

tumor.

Akt1Myr/KRasG12D mice had an overall increase in total macrophage infiltration and a higher
ratio of M2 to M1 macrophages, suggesting increased tumor surveillance.
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Eosinophils are critical for progression of fibrotic gastrointestinal diseases but are
understudied in pancreatic cancer. Recently, the first publication linking eosinophils to
pancreatitis initiation was published112. The findings suggest that blockade of IL-5 signaling
reduces the recruitment of eosinophils and thus the severity of pancreatitis in KRasG12D
mice with CCK injections112. Eosinophils have been shown to have cytotoxic properties
against tumor cells, or have pro-tumor properties by increasing Th2 and T-regulatory cell
populations. Eosinophils are often important in the progression of gastrointestinal
inflammatory diseases, and fibrotic lung and liver diseases59. Prior studies characterizing
the cytotoxic properties of eosinophils and pancreatitis have yet to be published.
The studies in chapter 3, further delineate the role of eosinophils in fibrosis and
pancreatic cancer. Akt1Myr/KRasG12D mice with experimental chronic pancreatitis have
increased eosinophil recruitment that is co-localized with the fibrotic regions of the stroma.
Eosinophils in Akt1Myr/KRasG12D mice lacked the cytotoxic surface marker NKG2D,
suggesting a pro-tumor role for these eosinophils. In contrast, KRasG12D mice, which lack
robust accumulation of fibrosis, have infiltration of eosinophils that express this cytotoxic
marker. These results should promote future studies determining if these non-cytotoxic
eosinophils are responsible for, or innocent bystanders of the extensive fibrosis and
accelerated tumor formation in the Akt1Myr/KRasG12D mice. The monoclonal antibody
against Siglec-F is efficient at depleting eosinophils in vivo54. Depletion of eosinophils prior
to CCK injections will yield results indicating the role of eosinophils in the formation of
desmoplasia and tumor formation. Characterization of the immune cell landscape here
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would provide further information on the potential orchestrating role that eosinophils
have in promoting a Th2 immune response.
Interleukin-5 is important for eosinophil and B-cell recruitment and activation.
Here, IL-5 was found expressed at low levels in acinar cells. ADM induction by CCK
injections increased IL-5 expression, however when cells continue to transform into PanIN
cells the IL-5 expression is reduced, and IL-5R expression is increased. IL-5R expression in
tumor cells was surprising because, its protein expression has only been previously
described on immune cells. Studies here show that IL-5R has potential clinical relevance
due to increased expression in patient PDAC samples. IL-5R also was found on human and
mouse cells lines. In trans-well experiments, IL-5 increases the migration of tumor cells
that express IL-5R.
Soluble IL-5 activated Stat-5 signaling in PDAC cells. Previous reports have shown
that down-regulation of Stat-5 results in inhibition of tumor growth in subcutaneous and
othotopic models of pancreatic cancer121. Moreover, cells with knocked-down Stat-5
expression in the orthotopic models have reduced tumor metastatic potential likely due to
these cells having reduced in vitro mobility121.
Cytokine signaling is generally studied in the context of immune cell activation, and
there is a lack of comprehensive studies in relation to cytokine effects on tumor cells.
Results from this study should potentiate more studies aimed at determining the direct
implications cytokines have directly on tumor cells themselves. More specifically, these
results elucidate the importance of IL-5 and IL-5Ra crosstalk directly related to pancreatic
tumor cells, which may present a novel pathway for targeting the inhibition of pancreatic
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tumor migration and to improve responsiveness to therapies. Future experiments are
important to determine how this novel crosstalk between IL-5 and IL-5Ra on pancreatic
tumor affects tumorigenesis. In bladder cancer, IL-5 induces migration and invasion
through Stat-5 mediated MMP-9 production120 and provides strong rationale for testing
this mechanism in pancreatic cancer cells. Expanding studies implemented here, MMP
inhibitors can be tested to determine their effects on migration and invasion of pancreatic
PDAC cells, and Stat5 inhibitors can be tested for their effects of MMP expression. These
studies would delineate the underlying mechanisms responsible for migration provoked by
IL-5 stimulation.
Previous studies that employed Jak2 inhibitor BMS-911543 distinctly inhibited
downstream Stat5 activation152. Although tumor cell lines had low sensitivity to BMS911543 in vitro, in vivo treatment resulted in inhibition of T-regulatory cell differentiation
and intra-tumor infiltration in vivo152. Although these studies resulted in minimal efficacy in
tumor bearing mice, there was a significant direct effect on the tumor microenvironment.
New studies using better Stat-5 pathway inhibitors may be more efficacious in reducing
tumor spread and growth by reducing invasiveness while modulating the immune
response. IL-5 signaling in eosinophils activate both Stat3 and Stat5. Since Stat-3 activation
is important in regulating tumor survival in many cancers, including pancreatic cancer,
further studies are important to determine if both of these signaling pathways are activated
in human pancreatic cancer. Thus, release of IL-5 in the local microenvironment may be
important in activation of two Stat pathways that contribute to survival mechanisms.

116

As previously discussed, pancreatic cancer’s dismal survival rate is in part due to a
lack of new therapeutic strategies. Current strategies only provide a modest increase in life
expectancy. Moreover, current therapeutics do not take into account the complex crosstalk
of immune cells and stromal cells in the tumor microenvironment. Polyamine-based
therapies, may overcome this challenge by inhibiting this complex microenvironmenttumor interplay while selectively inhibiting growth and metabolism of the tumor cells.
Here it is shown that DFMO in combination with PTI increased survival in an
orthotopic model of pancreatic cancer. Gemcitabine resistant tumor cells were used for in
vitro experiments and the results indicate that survival is increased with the DFMO-PTI
combination therapy through mechanisms of cell death and inhibition of proliferation. The
highly metastatic human pancreatic tumor cell line, L3.6pl, underwent increased apoptosis,
whereas murine tumor cells like Pan02 have reduced proliferation. Orthotopic models of
pancreatic cancer using both cell lines indicated similar results as determined by increased
immunohistochemical detection of cleaved caspase-3 (apoptosis) in L3.6pl tumors and
reduced Ki67 (proliferation) in Pan02 tumors.
Reduced responsiveness of L3.6pl tumors to the DFMO+PTI therapy compared to
Pan02 tumors may be in part due to the lack of a complete immune system in the NSG mice.
Data suggests that polyamine-modulating therapies have increased efficacy when in
murine models that can activate an anti-tumor immune response. DFMO+PTI treatment
was reported to increase anti-tumor immune cell infiltration including CD8+ T cells145.
Additionally, immunosuppressive T regulatory cells, myeloid derive suppressor cells and
M2 macrophages were reduced. Survival advantage from the combined therapy was lost
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when treatment was given to mice depleted of CD4+ and CD8+ T cells. Here we show that
DFMO and the combination of DFMO+PTI eliminated the immune surveillance by allowing
M1 macrophages to infiltrate the tumor while reducing T-regulator cell marker FoxP3 (see
Appendix, Figure 32). Combined, these studies support that polyamine blockade therapy
has anti-tumor immunomodulating activity.
In some cancers, traditional chemotherapeutics can induce immunogenic cell death,
which consequently activates the immune system to help combat the tumor. Unfortunately
this is not the case in pancreatic cancer. Gemcitabine extensively remodels the pancreas
tumor microenvironment by recruiting MDSCs153, and creating a Th2 cytokine
environment, which induces M2 polarization154. Future studies should be performed to
determine if combination of polyamine blockade therapy and chemotherapeutics could
reverse the pro-tumor microenvironment that promote and increase overall survival.
Overall, pancreatic cancer has a complex microenvironment with a milieu of
immunosuppressive immune cell infiltration responsible for tumor immune escape and
chemoresistance. Efforts have been undertaken to create novel immunotherapeutic
approaches to combat this this immunosuppressive environment. Namely, GVAX is an
allogenic irradiated whole-cell tumor vaccine transfected with GM-CSF gene, which also
delivers tumor-associated antigens. The rational for GVAX is that it will release GM-CSF to
promote T-cell, granulocyte, and monocyte cytotoxicity against tumor cells155. Clinical
studies employing GVAX in combination with chemotherapy have yielded disparaging
results. This is likely because GM-CSF is an important stimulating factor for pro-tumor
MDSCs156. Anti-PDL1 and anti-PDL-1 therapies are also unsuccessful in patients with
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pancreatic cancer, even through increased PD-L1 correlates with worse prognosis, tumor
grade and is inversely correlated with tumor infiltrating lymphocytes157. Pancreatic
desmoplasia also enhances chemoresistance in part due to its ability to enhance an
immunosuppressive environment, but also because it acts as a physical barrier restricting
the access to therapy158. Previous attempts at reducing fibrosis is hotly contested because
of the thought that early fibrosis is a defensive mechanism that acts to reduce tumor
spreading.
Overall, the work presented here sheds light on aspects of the pancreatic disease
progression, the role of the stroma-immune cell environment and how certain strategies,
such as DFMO/polyamine transport inhibition, may play a role in shifting the immune cellcytokine signaling interactions in the microenvironment. These findings validate the need
for further understanding of how immunomodulation can be used to design new
therapeutics that take into account the pancreatic tumor and
microenvironment.
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APPENDIX A: SUPPLEMENTAL FIGURES
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Figure 31: DFMO in combination with PTI reduced expression of ATP13A3.
Immunocompetent C57Bl/6 mice were orthotopically injected with 1 x 106 Pan02 cells.
Drug doses were 1% DFMO in the drinking water for 2 weeks and 1.8 mg/kg Trimer44NMe
PTI injected i.p. once daily for 5 days per week over 2 weeks. Immunohistochemistry for
ATP13A3 is shown. Scale bars on the 40x objective images correspond to 50 µm.
This figure is currently in submission in the following manuscript.
Gitto, S.B, Gesiotto, Q., Massaro, C., Pandey, Altomare, D.A., Geerts, D., Olive, K., Phanstiel O.
Altered polyamine metabolism leads to polyamine exchange between pancreatic ductal
adenocarcinomas and stroma and the opportunity for new intervention.
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Figure 32: DFMO and PTI combination therapy reduces immune surveillance and Tregulatory cell infiltration.
Immunocompetent C57Bl/6 mice were orthotopically injected with 1 x 106 Pan02 cells.
Drug doses were 1% DFMO in the drinking water for 2 weeks and 1.8 mg/kg Trimer44NMe
PTI injected i.p. once daily for 5 days per week over 2 weeks. Immunohistochemistry for
F4/80 (macrophages) FoxP3 (T-regulatory cells) are shown. Scale bars on the 40x
objective images correspond to 50 µm.
This figure is currently in submission in the following manuscript.
Gitto, S.B, Gesiotto, Q., Massaro, C., Pandey, Altomare, D.A., Geerts, D., Olive, K., Phanstiel O.
Altered polyamine metabolism leads to polyamine exchange between pancreatic ductal
adenocarcinomas and stroma and the opportunity for new intervention.
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